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Q U IL L

ON SCALPEL

Vol. 19

This section

provides a medium through which Canadian
surgeons can declare themselves, briefly and in
formally, on the day-to-day affairs of surgery.

TREATMENT OF CARCINOMA OF THE THYROID GLAND
I t is time that surgeons faced the facts
concerning thyroid carcinoma. Total thy
roidectomy is recommended in current
textbooks and training programs as the
treatment of choice for papillary or folli
cular cancers of the thyroid and some even
recommend radical neck dissection if any
local lymph-node spread is present. Advo
cates of total thyroidectomy seem undeterred
by the lack of evidence that the extent of
surgical resection influences the outcome.
Careful assessment of the available evidence
is required rather than opinions based on
traditional concepts.
Black, YaDeau and Wollner1 reviewed
418 cases of papillary carcinoma of the
thyroid in patients followed-up over a 30year period. The 10-year survival rates were
84 and 90% for patients with lesions greater
and smaller than 1.5 cm in diameter, re
spectively, regardless of involvement of
lymph nodes. The operations performed
ranged from a subtotal lobectomy to a total
thyroidectomy. Crile2 followed 107 conse
cutive patients with papillary cancer of the
thyroid for a median period of 11 years.
There were 10 deaths, all within 5 years of
the initial operation. The surgical procedure
varied but most patients had a lobectomy.
Medina and Elliott3 reported 130 cases
of thyroid cancer treated by operations
ranging from subtotal lobectomy to total
thyroidectomy with neck dissection, in ap
proximately equal numbers, by 24 different
surgeons. The survival could be related only
to the age of the patient at diagnosis and
the histologic type of the tumour. Complica
tions were related to the magnitude of the
operation, as would be expected. The 10year survival in cases of papillary or folli
cular lesions was similar to that reported by
others.1' 2> 4 No reports in the literature

suggest that radical local treatment for papil
lary or follicular lesions influences the prog
nosis, which is relatively good in any case.
Although medullary carcinoma of the thy
roid exhibits different behaviour with more
rapid progression, evidence that the extent
of resection alters the outcome is also
lacking.5
The presence of multiple foci of cancer
in the thyroid gland is often cited as an
argument for radical local treatment. No
body would dispute that multiple foci of
papillary cancer often can be demonstrated
histologically. The reported rate of multi
focal malignant lesions ranges from 30% 6 to
87.5% 7 and perhaps this figure would be
increased to 100% if the histologic search
were intensive enough. One must, however,
consider performance. It is rare for overt
carcinoma to develop in a residual thyroid
lobe.6 What, then, is the natural history
of these histologic foci of cancer stressed so
greatly by some surgeons? What of the rate
of histologically proven carcinoma in multi
nodular goitres that varies from 4 to 15%
in different series?8' 11 It is estimated that
thyroid nodules develop in approximately
5% of the adult population.12- 13 Accord
ing to Statistics Canada the annual death
rate from cancer of the thyroid between
1950 and 1973 has remained fairly constant
at around 6/1 million population.14’ 15
Even if one accepted the lowest figures for
reported cases of nodular goitres and malig
nant lesions one would have to deduce that
many people harbouring carcinoma in their
thyroid glands live a normal life span with
out overt evidence of the disease.
There are only two possible explanations
for these facts. First, in histologic appear
ance, a malignant tumour in many thyroid
specimens may be a normal variant, which
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is erroneously labelled “cancer” by the
pathologist. Second, differentiated carci
noma of the thyroid may indeed be common,
but if so, in most cases it must be confined
by some unknown mechanism to a strictly
localized microscopic disease. Whichever
explanation proves to be true, one must
conclude that radical operative procedures
on the thyroid gland are irrelevant. Eventu
ally immunologists may give us a better
understanding of these facts but in the
meantime the facts cannot be ignored.
It has also been argued that, for papillary
and follicular tumours, once surgical treat
ment is complete, an ablative dose of iodine131 (131I) should be given to eliminate any
residual thyroid tissue in the neck.16 This
is indeed aggressive therapy for such a dis
ease. What potential benefit to the patient
is evidenced by such treatment in exchange
for its discomforts and hazards?
At the opposite end of this histologic
spectrum, anaplastic thyroid tumours pre
sent a dismal prognosis. No form of therapy
appears to influence the disastrous course
except for short-term palliation. Why, then,
do many surgeons recommend aggressive
surgical and radiation therapy?
The message is clear. Papillary or folli
cular carcinoma of the thyroid should be
locally excised. In most cases this means a
subtotal or total lobectomy depending on
the size of the tumour in relation to the
size of the thyroid lobe: the remainder of
the gland should be left alone if it is normal
to palpation. Lymph nodes should be re
moved singly or in groups only when they
contain tumour. The theoretical rationale
for the use of thyroxine therapy is reason
able, though again it remains to be proved
that thyroxine reduces the rate of clinical
recurrence. Ablative 131I therapy should
be used only in patients with overt evidence
of widespread disease. For anaplastic tu
mours therapy should be designed to offer
meaningful palliation if and when possible.
The concept that the outcome for a pa
tient with cancer is largely dependent on
the extent of the surgeon’s intervention is
indeed attractive as a raison d’etre for sur
gical intervention. The evidence, however,

Vol. 19

suggests otherwise and any surgeon perform
ing radical procedures for carcinoma of the
thyroid gland must ask himself what he is
attempting to achieve in the light of the
natural history of the disease.
C h a r l e s J. W r ig h t , MB, FRCS[C], FRCS
(Eng), FRCS(Edin)
Department o f surgery,
University Hospital,
Saskatoon, SK
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When used for primary treatment of rectal
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pelvic exenteration is not an effective pro
cedure to treat recurrences after abdomino
perineal resection.
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R EVIEW A R T IC L E

GASTROINTESTINAL HORMONES*
STEPHEN N. SU LLIVAN , M D f
The availability of pure intestinal hormones and
the development of radioimmunoassays for their
measurement has expedited research into many
aspects of gastrointestinal endocrinology. A
complex balance evidently exists between the
different intestinal hormones and also the rest
of the endocrine system. Polyendocrinopathies
have been described, and, so far, two diseases
due to intestinal hormone excess (ZollingerEllison syndrome and the syndrome of watery
diarrhea, hypokalemia and achlorhydria] eluci
dated. It seems likely that many more gastro
intestinal endocrine diseases await discovery.
La disponibilite d’hormones intestinales pures et
la mise au point de methodes radio-immunologiques pour en faire le dosage ont stimule la
recherche dans plusieurs champs de I'endocrinologie gastro-intestinale. Un equilibre complexe
existe evidemment entre les differentes hor
mones intestinales tout comme le reste du systeme endocrinien. Des polyendocrinopathies ont
ete decrites et jusqu’a maintenant, on a pu
elucider deux maladies causees par une hyper
secretion d'hormone intestinale (le syndrome
de Zollinger-Ellison et le syndrome de diarrhee
liquide avec hypokaliemie et achlorhydrie). II
semble probable que plusieurs autres maladies
endocriniennes gastro-intestinales seront decouvertes.

I t is now evident that not only is the gastro
intestinal (GI) tract a major endocrine or
gan 1 but also that there are complex rela
tions between intestinal hormones and other
endocrine organs. Two elaborate reviews on
the subject have recently become avail
able,2’ 3 and, in another publication, I pub
lished a brief summary. 4 The pertinent lite
rature is made complex by interspecies vari
ations and by the experimental use of nonphysiologic doses of impure hormones. In
this paper I shall try to confine discussion
to data obtained, where available, from the
use of relatively pure hormone preparations
in man.
A pud C e lls

The endocrine polypeptide cells of the
*From the gastrointestinal unit, Victoria Hospital,
University of Western Ontario, London, ON.
tPresent address: Liver unit, King’s College Hos
pital, London, England.

T A B L E I.— H ormones P roduced by A pud C ells
Cell type

Hormone produced

Gastrin, secretin, C C K .
“ enteroglucagon” ,
G IP , VIP, motilin
Pituitary melanotroph MSH
Pituitary corticotroph A C T H
Calcitonin
Parafollicular C cell
Insulin
Pancreatic p cell
Glucagon
Pancreatic <X2 cell
Gastrin
Pancreatic ai cell
Adrenal medulla
Carotid body
“ Endocrine cells’ ol
the lung

G ut polypeptide cells

gut belong to a family of cells to which,
from their cytochemical and ultrastructural
characteristics, the acronym Apud (amine
precursor uptake and decarboxylation) re
fers. These cells, also found in the pituitary,
thyroid and adrenal glands, and the pan
creas and lungs 5 (Table I) are believed to be
of neuroectodermal origin and to migrate
from the neural crest. 6 The common origin
of these cells may partially explain both
the common amino-acid sequences in dif
ferent hormones and some of the polyen
docrinopathies — Wermer’s syndrome (pi
tuitary adenoma, islet cell tumour, para
thyroid adenoma or hyperplasia) and Sip
ple’s syndrome (medullary thyroid carci
noma, pheochromocytoma, parathyroid ade
noma or hyperplasia).7, 8 Tumours of this
cell series have been termed apudomas . 9
The nomenclature for these cells is com
plicated and is in a state of flux; the trend
seems to be to name the cells for the hor
mone they produce.
M o d e o f A c t io n o f G I
H orm ones

The mechanism of release of G I hor
mones is not known but evidence points to
cholinergic and adrenergic pathways. A nti
cholinergics inhibit the pancreatic secretory
response to secretin releasers more than the
response to exogenously administered secre
tin ; 10 topical anesthetics applied to the in
testinal mucosa reduce the response of the
pancreas to intestinal stimulants, 11 and
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hexamethonium prevents the release of
cholecystokinin (CCK).1- Infusions of phys
iologic doses of adrenalin are known to re
lease gastrin,13 an effect that may be in
hibited by !3 blockade. In the future,
stimulators and inhibitors of Gl-hormone
release may be of therapeutic value in the
management of diseases of Gl-hormone defi
ciency and excess, which are sure to be
described.
Gl-hormone receptors have not been de
scribed but Grossman14 has postulated that
gastrin, CCK, secretin and glucagon act on
one receptor with two interacting sites. Gas
trin and CCK, which share a terminal pentapeptide, are thought to act at one site, and
secretin and glucagon, which also have
structural similarities, at the other. The re
sult of a simultaneous action of hormones
depends on whether it leads to competitive
or noncompetitive augmentation or inhibi
tion.
Gastrin and CCK are believed to act on
the lower esophageal sphincter (LES) and
small bowel by stimulation of postganglionic
cholinergic neurons.13 Their action on the
gallbladder, however, may be through direct
stimulation of the muscle.16 One intestinal
hormone, motilin, may act through direct
release of acetylcholine from nerve end
ings.17
The histamine HL>-receptor antagonists
metiamide and cimetidine are universal
blockers of all gastric secretory stimuli, in
cluding vagal stimulation, gastrin, choli
nergic agents, histamine and food,18' 19 and
it may be that histamine is the final step in
the mode of action of all gastric stimulants.
Biochemically, the mode of action of in
testinal hormones is still speculative. Cyclic

adenosine monophosphate (AMP) is a fac
tor in intestinal secretion29 and prostaglan
din activity,21 and, while it is probably
true that cyclic nucleotides mediate some
of the action of intestinal polypeptide hor
mones, there is still not sufficient proof
to implicate them.
P roven GI H ormones

Gastrin, the most extensively studied of
the GI hormones, exists in several molecular
forms (Table II22‘2i’); however, the nomen
clature for the different forms has not been
standardized and each investigative group
uses its own terms.
Three gastrin species have, by means of
gel filtration, been reliably identified — gas
trin-34, gastrin-17 and gastrin-13 — accord
ing to the number of amino-acid residues
they contain.22 The C-terminal amino-acid
sequences of each molecule are identical
and each may exist in a sulfated or nonsulfated form.
Gastrin-34 corresponds to the “big gas
trin” of Yalow and Berson.26 It is the
major circulating form of gastrin in the
fasting state and its secretion is stimulated
by feeding; its half-life is reportedly 9 to
15 minutes.27' 28 Gastrin-17, the heptadecapeptide form, is also released by feeding
and has a serum half-life of 3 to 5 minutes.
Gastrin-13 is a “minigastrin” with a short
half-life of 1.8 minutes.25- 29 Gastrin-34
and lesser amounts of gastrin-17 are the
major circulating forms in pernicious anemia
and the Zollinger-Ellison syndrome (ZES).
Three other forms of gastrin have been
found in the circulation and in tissues. The
biologically inactive N-terminal tridecapepof

G astrin

In vestig a tive grou p a n d nom enclature

R ehfeld 23

mixture of
large molecules

Y alow 24

“Big, big
gastrin”

Component I

—
“Big gastrin”

Gastrin-34

Component II

Gastrin-17

Component III

Gastrin

Gastrin-13

Component IV

—

A

Gastrin

TABLE II.—Species

W a lsh -2

Vol. 19

P roperties

Gregory 25

G ram
fo rm u la
weight

A m in o
a cids

Release
by food

Ti
{m in )

90

—

20 000

?

No

—

Similar to
proinsulin

?

?

?

“Big gastrin”

~3900

34

Yes

9-15

“Little gastrin”

~2100

17

~1600

13

Yes
?

3-5

“Minigastrin”

1.8

4
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tide of gastrin-17 has been identified by
selective radioimmunoassay in the serum
of patients with gastrinoma.30 A “big, big
gastrin” found in the jejunum and serum
of healthy individuals and in the serum and
tumour tissue of patients with gastrinoma
has been isolated by Yalow and others-4’ 31
from the void volume of Sephadex gel
filtration columns; serum concentrations are
not affected by feeding and this form of
gastrin circulates with a half-life of ap
proximately 90 minutes. Rehfeld, Stadil and
Vikelsoe32 and Rehfeld23 have found a
gastrin designated Component I, that, since
it elutes just before gastrin-34 on Sephadex
G50-SF columns, is presumably larger than
gastrin-34. These workers, however, have
not been able to identify a homogeneous
“big, big gastrin” and they suggest that it
may be a heterogeneous mixture of gastrin
species of differing sizes.32
Gastrin exists in large quantities in the
gastric antral G cells and proximal duode
num and in lesser amounts in the gastric
cardia, pancreatic islet D or
cells, and
in progressively diminishing amounts along
the intestinal mucosa.33 The relative amounts
of the larger molecular species appear to
increase further down the intestine.
The major stimuli for gastrin release are
those associated with eating — vagal stimu
lation, antral distension and the contact of
protein products with the gastric antrum.
Besides these physiologic stimuli several
pharmacologic stimuli are also known to
release gastrin, including calcium (intrave
nous or oral),34 epinephrine13 and bile
salts.33 The release of gastrin by epine
phrine has been suggested as the explana
tion for elevated gastrin levels in pheochromocytoma36 and for the release of gastrin
during insulin hypoglycemia after complete
vagotomy.37- 38 These effects may be pre
vented by either a or (3 blockade.36' 39
Inhibition of gastrin release follows acidifi
cation of the gastric antrum to a pH below
3. (Alkalinization of the antrum may en
hance gastrin release by preventing feed
back inhibition by acid, and the loss of
antral acidification in pernicious anemia
and atrophic gastritis leads to sustained gas
trin release and high serum levels; elevated
gast.xt levels have also been reported in
rheumatoid arthritis40 but the reason for

this elevation is not known.) Glucagon41’ 42
and secretin,43’ 44 which normally decrease
gastrin release (and inhibit the action of gas
trin), cause a paradoxical increase in patients
with ZES. This has been suggested as a
diagnostic test for this syndrome, as has
calcium infusion.45
Recently, serum concentrations of cal
citonin, the hypocalcemic hormone produced
by the parafollicular C cells of the thyroid,
have been shown to be elevated in ZES.
Conversely, medullary carcinoma of the
thyroid, a calcitonin-producing tumour, is
associated with low serum-gastrin concentra
tions.46 These data suggest that gastrin
stimulates calcitonin release and that cal
citonin, in turn, inhibits gastrin release. As
well as inhibiting gastrin release in large
doses, calcitonin also inhibits the acid secre
tory effects of gastrin in smaller doses.47
Anticholinergics, such as atropine, will
block the vagal release of gastrin but will
not prevent gastrin release during feeding.
Anticholinergics will also impair the gastric
secretory response to gastrin.
The major physiologic effects of gastrin
appear to be related to gastric secretion of
acid, pepsin and intrinsic factor. Gastrin
may also be a major determinant of pres
sure in the normal LES,48 though there is
controversy on this point.49’ 50 Other secre
tory and motor effects have been observed
on the pancreas, biliary tree and intestine
(Table I II 51' 53). Gastrin also has trophic
effects on the stomach, duodenum and pan
creas54' 56 and stimulates the secretion of
secretin,57 insulin58 and calcitonin.59 At
present, these actions appear to have minor
physiologic significance.
The sites of gastrin degradation have not
TABLE III.— A ctions

of

G astrin

Secretory
Acid, pepsin and intrinsic-factor secretion
Pancreatic enzyme production
Increase in bile flow
Secretin stimulation, insulin and calcitonin release
Decrease in intestinal salt and water absorption61
Motor
Increase in LES pressure
Increase in gastric motility
Relaxation of ileocecal valve and sphincter of
Oddi62
Weak intestinal motility stimulant63
Miscellaneous
Trophic effects on stomach, duodenum and pan
creas
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been fully defined, but evidence suggests cagon and insulin secretion78 but highly
that the small bowel,60 gastric fundus61 and purified CCK has no effect.2
kidney62"64 are important in gastrin clear
Research into the effects of CCK has
ance. These organs59' 60' 61' 63 appear to been hampered by the lack of a reliable
extract gastrin during stimulated gastrin re radioimmunoassay for the hormone and of
lease but not under basal conditions. Neph readily obtainable pure hormone. Commer
rectomy prolongs the half-life of gastrin,62 cially available CCK preparations may con
and patients with acute63 and chronic tain only 20% by weight of CCK. Radio
renal failure66 have elevated basal gastrin immunoassays for CCK have been re
levels. In our laboratory prolonged cir ported79- 80 but these have not yet been
culation of gastrin has been demonstrated proved reliable. Thus, biologic assays have
in uremic patients following a test meal.67 been used for CCK and, experimentally, the
The loss of gastrin-degrading function in ure synthetic octapeptide of CCK or cerulein
mia may not be related to loss of glomerular (a decapeptide structurally similar to CCK
filtration rate, but to the loss of normal func and obtained from the skin of the Australian
tioning renal mass.68 The liver appears not tree frog Hyla caerulea) are frequently used.
to be a major degrader of gastrin and, in
Secretin
contrast to the rapid inactivation of pentagastrin by the liver, exogenous and endoge
This topic was reviewed in 1972 by
nous gastrin are not appreciably affected by Hubei.81
passage through the portal circulation.69' 70
Secretin is a 27-amino-acid polypeptide.
Fourteen
of the amino acids occupy the
Cholecystokinin
same position in secretin as in glucagon.
Cholecystokinin is a 33-amino-acid poly Secretin is produced by the small granular S
peptide, released from the mucosa of the cells in the transitional zone between the
upper small bowel by the hydrolyzed prod crypts and the villi of the upper small
ucts of fat and protein digestion, by high bowel.82
concentrations of acid,71 and possibly by
The chief stimulus for release of secretin
magnesium sulfate.72 The five C-terminal is duodenal acidification. The threshold for
amino-acid residues are similar to gastrins. release is approximately pH 4.5 and the
This structural similarity to gastrin may ac amount of secretin released is believed to
count for some of the effects of CCK. In be related to the rate of acid input and,
the presence of gastrin, CCK may act as a hence, the length of bowel acidified. (How
competitive antagonist of gastrin but in its ever, the physiologic role of acid alone
absence acts as a partial agonist of some in stimulating secretin release has been ques
of the effects of gastrin.
tioned,83 since the pH necessary for such
The major effects of CCK (Table IV 73" release may not be present in the postcibal
75) relate to stimulation of pancreatic en period.) Secretin may also be released by
zyme secretion and contraction of the gall protein,84 gastrin and bile salts.80 The ques
bladder. It also has motor effects on the tion of whether secretin is released by vagal
sphincter of Oddi, small intestine,72 stimulation or the products of fat diges
colon67 and pyloric sphincter.77 Impure tion has not been resolved.
preparations may stimulate pancreatic gluThe main physiologic effect of secretin
is
stimulation
of pancreatic volume and elec
T A B L E IV. —Actions of C holecystokinin
trolyte secretion. Besides its effects on the
pancreas, secretin has positive and negative
Pancreatic enzyme secretion
Gallbladder contraction
secretory and motor effects elsewhere in the
Relaxation o f sphincter of Oddi
GI
tract (Table V 73"76- 86"90). n decreases
Intestinal and colonic motility
the release of gastrin91 and acts as a non
Increase in pyloric sphincter pressure
Competitive inhibition of gastrin
competitive inhibitor of gastrin on the gas
Stimulation of gastric secretion in absence o f gastrin
tric parietal cells and the LES.92
Release of alkaline phosphatase from small
intestine73
Secretin may be a factor in the patho
Release o f intestinal disaccharidases74
genesis of peptic ulcer. The positive ino
Small intestinal secretion76
tropic effects of secretin on the pyloric
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gon.105 Whether it stimulates insulin re
lease has not been resolved, but available
evidence suggests that it does not, since
galactose, fructose, xylose, mannose and
3-0-methyl glucose all raise serum levels of
enteroglucagon without affecting insulin
levels.106
An enteroglucagon-producing renal tu
mour, causing severe small and large bowel
stasis with marked hypertrophy of the small
intestinal villi, has been reported. Following
removal of the tumour all abnormalities re
mitted.107, 108
The physiologic role of enteroglucagon is
unknown. It has been suggested that its
release from the lower small intestine may
“act to produce a slowing of further food
transport and also to enhance long-term
growth of the absorptive intestinal mu
cosa”.109
Gastric Inhibitory Polypeptide
Gastric inhibitory polypeptide (GIP) is a
43-amino-acid polypeptide, with structural
similarities to porcine secretin and glucagon,
which has been isolated by Brown and
Dry burgh110 from an impure preparation
of porcine CCK. It has been identified by
radioimmunoassay in the serum of m an111
and is believed to be released from the D x
cells of the upper small bowel mucosa112
by food, particularly glucose and fat.113
In microgram doses it inhibits both an
tral and fundic motor activity and the gas
tric acid and pepsin secretory response to
pentagastrin, histamine and insulin hypo
glycemia.114 GIP is believed to stimulate
intestinal secretion,115 and one case of pan
creatic cholera has been attributed to a
T A B L E V .— A ctions of S ecretin
GIP-producing tumour.116 No effect has
been observed on the gallbladder or exo
Secretory
crine pancreas, but recently intravenous in
Pancreatic volume and bicarbonate secretion
Increase in bile flow
fusion of GIP has been demonstrated to
Pepsin secretion
potentiate the insulin secretory response to
Brunner’s-gland secretion
Increase in jejunal secretion and decrease in ab intravenous glucose.117
sorption75, 86
The physiologic implications of GIP will
Decrease of gastric secretion
be discussed under the section on enterogasRelease of insulin87
Decrease in stimulation of gastrin
trone.
Release of alkaline phosphatase from brush
Vasoactive Intestinal Peptide
border73
Release of intestinal disaccharidases74
Vasoactive
intestinal peptide (VIP) is a
Elevation of serum calcium concentration88
Motor
28-amino-acid polypeptide with structural
Decrease in LES pressure
similarities to glucagon, secretin and
Decrease in gastric motility 89
G IP.118 These structural similarities are
Decrease in small bowel9 0 and colonic motility76
Increase in pyloric sphincter pressure
related to its different actions, which in-

sphincter93 may be important in preventing
duodenogastric reflux, which is thought to
be of etiologic significance in gastric ulcer.94
Impaired secretin release has been demon
strated in patients with duodenal ulcers95
while exogenous secretin is a strong inhi
bitor of meal or pentagastrin-induced gas
tric secretions in such patients.96
Enteroglucagon
A substance with glucagon-like immunoreactivity has been identified in the intes
tinal mucosal L cell, gastric mucosal A cell
and in plasma.97, 98 There are species vari
ations in mucosal location, and its exact
location in man has not been identified. It
appears, however, that the largest quantities
are found in the ileum.99 It can be distin
guished from pancreatic glucagon by selec
tive immunoassay and by its molecular
weight (approximately 7000), which is twice
that of a major pancreatic glucagon frac
tion.100 Like gastrin, it may exist in small
and large molecular forms.101
Unlike pancreatic glucagon, it is released
into the circulation by glucose98 and longchain triglycerides.102 After a partial gas
trectomy103 or vagotomy and pyloro
plasty104 (particularly in patients with a
“dumping syndrome”) and in patients with
essential alimentary hypoglycemia (vide
infra) large amounts of enteroglucagon may
be liberated into the circulation following
the ingestion of carbohydrates.
Enteroglucagon appears to be devoid of
glycogenolytic activity and it has been hypo
thesized that it may competitively inhibit
the hepatic actions of pancreatic gluca-
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elude stimulation of pancreatic and intes
tinal secretion,115 induction of hypergly
cemia119 and inhibition of gastric acid and
pepsin secretion. It also has vasodilatory
activity, from which it derives its name,120
and inhibitory effects on tracheal, gastric
and gallbladder smooth muscle.
VIP was originally isolated from the up
per porcine small intestine but has now
been demonstrated by radioimmunoassay to
be distributed throughout the primate gut
in quantities exceeding that of gastrin, secre
tin, or CCK.121
The physiologic function of VIP is
presently unknown but, pathologically, it
has been shown to be associated with the
syndrome of watery diarrhea, hypokalemia
and achlorhydria (WDHA) secondary to
pancreatic or retroperitoneal neoplasms.122123

Motilin
Motilin is a 22-amino-acid polypeptide
that has been isolated from the mucosa of
the upper 1 m of the porcine small intes
tine.124- 125 Its structure is distinct from
that of the other gastrointestinal polypep
tides.126 Intravenous injection of nano
gram doses in dogs leads to increased gas
tric antral and fundal motor activity and
increased pepsin output with no increase in
acid secretion.124 In the dog the stimulus
for its release is believed to be increased
alkalinity of the duodenum.127 However,
in man, two recent reports suggested that
motilin may be released by duodenal acidifi
cation128 and in fact delay gastric empty
ing. 129 The mode of action of motilin may
lie in release of acetylcholine from nerve
endings.1 ' The physiologic role of motilin
is presently unknown but it may function
as a regulator of constant gastric input into
the duodenum.
Prostaglandins
Prostaglandins are oxygenated cyclic C20
fatty acids and, as such, are not polypeptide
TABLE VI.—E ffects
Prostaglandin Fia.

Increase in LES pressure140
Contraction of circular and longitudinal
smooth muscle
stimulation of intestinal secretions

of
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intestinal hormones. They are mentioned
here only because under certain pathologic
and pharmacologic circumstances they
exert a hormonal effect on the GI tract.
The effects of prostaglandins on the gut
have been reviewed by Waller,130 Bennett
and Fleschler131 and Wilson.132 There is
evidence both for the synthesis, release
and degradation of prostaglandins in the
gut and for action of ingested or injected
prostaglandins on the gut. However, pros
taglandins have not been demonstrated to
act as GI hormones under normal physio
logic conditions. Prostaglandins E 2 and F 2 a
are the major extractable forms found in
the GI mucosa and pancreas of man. Their
function is unknown, but it is suggested that
they may act as local mediators of secretion
and motility. The mode of action of prosta
glandins is also unknown, but there is sub
stantial evidence to suggest that they act
through stimulation or inhibition of adenyl
cyclase and hence, the “second messenger”
cyclic AM P.21
The diarrhea that may be associated with
thyrojd medullary carcinoma, ganglioneu
romas, pheochromocytomas, islet cell tu
mours and ileal carcinoids may result from
prostaglandin production and release by
these tumours.133- 134
Prostaglandins E 1; E 2 and A x have gas
tric antisecretory effects during basal and
stimulated gastric acid secretion.135' 138
Prostaglandin analogues that are potent and
orally active with few side effects may be of
therapeutic benefit in gastric hypersecretory
states139 and it is possible that the ulcero
genic effects of acetylsalicylic acid and indomethacin may be related to their inhibitory
action on prostaglandin synthesis.
Some of the other effects of exogenously
administered prostaglandins in man are
listed in Table V I.140
H ypothetical GI H ormones
The existence of two hormones, “incre
tin” and “enterogastrone”, has been postuP rostaglandins

in

r

\
4

1

M an

Prostaglandin E \

Relaxation of LES
Contraction of longitudinal and relaxation
of circular smooth muscle
Stimulation of intestinal secretion
Inhibition of basal and stimulation of acid secretion

4
V
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lated to explain the observed physiologic
effects that follow eating, including aug
mented insulin secretion and feedback in
hibition of gastric secretion and motility.

Incretin
This topic has been well reviewed.2’ 141'
144 It is established that, for a given eleva
tion in blood sugar concentration, oral ad
ministration of glucose leads to a higher
and more sustained insulin response than
intravenous administration.145’ 146 The
same is true for amino acids.147 It is pre
sumed that the augmented insulin response
is due to hormonally stimulated insulin re
lease. Secretin,87 impure CCK, gastrin,58
glucagon, G1P,117 VIP and duodenal ex
tracts (insulin-releasing polypeptide)148 are
all capable of stimulating insulin secretion.
It is not known which (if any) of the GI
hormones is a true physiologic intestinal
insulin secretogogue. Several hormones may
act in concert to produce the observed ef
fects. Release of these hormones may be
inducible since carbohydrate restriction will
blunt the insulin response to an oral glucose
tolerance test.149 The biguanide, phenformin, may inhibit insulin release after food
by inhibition of intestinal hormone re
lease150 as well as by impaired glucose ab
sorption.151 The clinical ramifications of
incretin will be discussed further under the
section on alimentary hypoglycemia.
Enterogastrone
The introduction of fat, acid or hyper
tonic solutions into the duodenum is known
to inhibit the gastric secretory response to
gastrin, pentagastrin, histamine, insulin hy
poglycemia and a meal. The term “entero
gastrone” is applied to a hormone that,
when released from the duodenal mucosa,
would inhibit gastric secretion. Several pos
sibilities exist (Table VII), including secre
TABLE VII.—Actions

of

tin,90 CCK, GIP and glucagon. Other in
hibitors of gastric secretion have also been
described including sialogastrone (isolated
from saliva152), bulbogastrone (isolated
from the duodenal bulb152), gastrone B
(found in human achlorhydric gastric juice
and identified in the antral mucosa153- 154)
and urogastrone (isolated from urine). The
function of these substances is unkown.
Of all the possible enterogastrones, the
GIP of Brown110 is the most likely can
didate. It alone (and perhaps VIP) inhibits
the secretory response to all known gastric
stimulants as well as inhibiting gastric moti
lity. Under physiologic circumstances, how
ever, enterogastrone may comprise several
hormones acting in concert to produce the
observed effect of inhibition of gastric secre
tion and motility.
A natomical Loci

of

A ctivity

The multiple and varied effects of the
intestinal hormones on the stomach and
pancreas have been extensively investigated
and described. It is only in recent years
that more interest has been directed towards
the LES, pyloric sphincter and large bowel.
These aspects will be considered more fully.

Lower Esophageal Sphincter
Since the advent of continuous-perfusion
esophageal manometry,155 the physiologic
and pharmacologic properties of the LES
have been more accurately defined.156 The
chief function of the LES is to maintain a
pressure barrier between the gastric cardia
and the body of the esophagus. Positive
inotropic influences are exerted on the
sphincter by increased intragastric pressure,
vagal stimulation, cholinergic drugs, alpha
adrenergic drugs,157 metoclopramide,158
prostaglandin Fs*159 and gastrin.160 Gas
trin is the influence of major pharmacologic

P ossible E nterogastrones
Hormone
CCK

Secretin

Glucagon

GIP

..........

Fat, acid

Acid

Hypoglycemia

Fat

..........

+

+

Variable factor
Acid inhibition response to

—

Inhibition of gastric motility...................... ..........
Inhibition of pepsin...................................... ..........

+
+

+

+
—
+
V

+
+
+
+
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(and perhaps physiologic) importance and
probably acts via stimulation of postgangli
onic cholinergic neurons. Negative inotropic
effects are exerted by secretin , 9 2 gluca
gon, 1 6 1 CCK , 1 6 2 beta adrenergics, 1 5 7
anticholinergics, 1 5 6 prostaglandins E 1; E 2
and A 2 , 1 6 3 smoking 1 6 4 and the ingestion
of fatty food . 1 6 5
Changes in intragastric pH also affect
LES pressure, but whether these pressure
changes are secondary to changes in serum
gastrin levels or not is unclear. Higgs, Smyth
and Castell1 6 6 have observed pH-dependent
sphincter-pressure changes without appreci
able alteration in total serum gastrin as
measured by radioimmunoassay. However,
presently available immunoassays are not
able to distinguish between the different
gastrin species, so changes in the molar ratio
of the different molecular species (and
hence, biologic activity) may occur without
affecting the total gastrin. This problem re
mains to be solved.
A number of patients with gastro
esophageal reflux have a hypotensive LES
that responds poorly to stimuli (the hypo
tensive, hyposensitive LES); the presence or
absence of a hiatal hernia appears to be
of little importance . 1 6 7 The disorder may
be a combination of relative hypogastrinemia
and end-organ resistance to gastrin. Post
prandial (and possibly fasting) gastrin con
centrations may be diminished while exo
genous administration of gastrin causes
little absolute increase in LES pressure.168’
1 6 9 However, the exact physiologic mechan
ism of gastroesophageal reflux is unknown.
On the other hand, the disorder of
achalasia is characterized by the presence
of a hypertensive, hypersensitive LES , 1 7 0
which may fail to relax on swallowing. In
hibition of gastrin release via antral acidifi
cation will decrease the sphincter pres
sure . 1 7 1 Paradoxically, patients with per
nicious anemia or ZES, diseases in which
the serum gastrin values are grossly ele
vated, have sphincters of different com
petence. Poor sphincter function is found in
pernicious anemia 1 7 2 while patients with
ZES have excellent sphincter function.173’
174

Stomach

The actions of the polypeptide hormones
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on the gastric parietal cell and antral pump
have been discussed. Gastrin stimulates
both secretory and motor activity while
secretin, CCK, glucagon and GIP inhibit
both actions.
Pyloric Sphincter

The pylorus is a true sphincter and has
a function in preventing duodenogastric re
flux. 9 3 Pyloric pressure may be increased
by intraduodenal instillation of acid, olive
oil, amino acids, glucose and hypertonic
solutions. Likewise, exogenous administra
tion of secretin, and CCK increase pyloric
sphincter pressure . 77 Gastrin inhibits the
effects of these hormones. 1 7 5 Smoking will
also decrease pyloric sphincter pressure. 1 7 6
Pyloric sphincter incompetence and reflux
of duodenal contents may influence the
development of gastric ulcers.
Pancreas

Several reviews of the hormonal control
of pancreatic function have recently been
published.71’ 7 8 The chief hormonal influ
ences on the pancreas are as follows. Secre
tin increases the volume of pancreatic secre
tions and bicarbonate and insulin secretion
while CCK stimulates pancreatic enzyme
and glucagon release. Glucagon inhibits
pancreatic exocrine function by influencing
enzyme release and synthesis. Insulin, on
the other hand, appears to have trophic
effects on the pancreatic acinar cells. The
physiologic role of the other GI hormones
on pancreatic function is unknown.
Large Bcrwel

As already mentioned, at least two in
testinal polypeptides affect the function of
the colon. Intravenous infusion of CCK 1 7 7
or its endogenous release via oral adminis
tration of magnesium , 1 7 8 or duodenal in
fusion of fats and amino acids1 7 9 will
stimulate sigmoid colonic motility. Infusion
of secretin will inhibit the motor response
to CCK . 7 6 Neither of these hormones is
believed to act on the rectum. Gastrin is
not thought to have a motor effect on the
large bowel.
The implications of the colonic effects of
GI hormones will be considered in a dis
cussion of the irritable bowel syndrome.
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GI H o rm o nes in D ise a s e
An excess or deficiency of GI hormones
will have varied manifestations. Only five
disorders will be mentioned here: celiac
disease, peptic ulcer disease, pancreatic
cholera, alimentary hypoglycemia and the
irritable bowel syndrome.
Hormone Deficiency

Theoretically, any disorder that damages
the upper intestinal mucosa could lead to
secondary deficiency of small bowel hor
mones. At first glance, celiac disease or
gluten-induced enteropathy appears to
be such a disorder. Hypofunction of the
pancreas1 8 0 ' 1 8 2 and gallbladder183, 1 8 4
following oral administration of hormone
releasers has been described in celiac dis
ease. These physiologic alterations would
imply deficiency of secretin and CCK; how
ever, Polak and colleagues1 8 5 have de
scribed hypertrophy and hyperplasia of the
intestinal secretin cells in celiac disease,
suggesting possibly a poor release reaction.
On the other hand, Low-Beer and asso
ciates1 8 0 have demonstrated abnormally
high fasting levels of CCK with a slow rise
to normal levels following feeding in celiac
disease. These results remain to be con
firmed and explained.
Secretin deficiency has been proposed as
an etiologic factor in peptic ulcer disease,
and a deficiency of enterogastrone may ac
count for the increased incidence of in
testinal ulceration in celiac disease. 1 8 7
As techniques improve, true primary and
secondary deficiencies of GI hormones are
likely to be described.
Peptic Ulcer Disease

Except for ZES, the role of intestinal
hormones in peptic ulcer disease has not
been fully defined. Gastrin may be a factor
in the gastric hyperacidity observed in duo
denal and distal gastric ulcers. 1 8 8 Recently,
McGuigan and Trudeau1 8 9 have demon
strated that patients with duodenal ulcer
disease have an increased gastrin response
to a standard protein meal, increased sen
sitivity to pentagastrin1 9 0 and a higher and
more prolonged gastrin response to insulin
hypoglycemia. 1 0 1 Unlike ZES patients,
they have neither fasting hypergastrinemia
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nor a paradoxical gastrin secretory response
to glucagon and secretin. The possibility
that the hypersecretion of duodenal ulcer
disease results from deficient enterogastrone
has also been considered1 9 2 and it is of
interest that Bloom and Ward 9 5 have dem
onstrated deficient secretin release in a
small group of duodenal ulcer patients.
It has been postulated that gastric ulcers
may be due to pyloric sphincter dysfunction
and duodenogastric regurgitation of bile
and intestinal juices. 77 Damage to the mu
cosa would allow back diffusion of hydrogen
ions into the mucosa, thus explaining the
hypoacidity frequently noted in these pa
tients. The hypoacidity, in turn, would en
hance gastrin release, 1 9 3 which could then
block the normal pyloric response to CCK
and secretin. 1 7 5
Peptic ulcer disease also has a strong
association with chronic renal failure, 1 9 4
cirrhosis and portosystemic shunting, and
massive small bowel resection.195, 1 9 6 The
peptic ulcer disease of chronic renal failure
may be due to hypergastrinemia66 and gas
tric acid hypersecretion secondary to im
paired renal degradation of gastrin. 6 1 ' 64
There is, however, no direct correlation be
tween hypergastrinemia and the presence
or absence of peptic ulcer disease. 6 7 Simi
larly, the gastric hypersecretion that follows
massive small bowel resection may be due
to hypergastrinemia secondary to impaired
extraction of endogenous gastrin by the small
bowel, 60 or to enhanced secretion of gastrin
secondary to a deficiency of small bowel
gastrin secretory inhibitory substances. 1 9 7
Gastrin is not affected by passage through
the portal circulation7 0 and hypergastrine
mia has not been documented in cirrhosis
or following portosystemic shunting. The
gastric hypersecretion that occurs in these
situations may be secondary to increased
sensitivity of the gastric parietal cell mass
to normal levels of circulating gastrin. 1 9 8
Surgical modifications of the upper gas
trointestinal tract will affect gastrin levels.
After vagotomy (truncal, selective or highly
selective) basal and postcibal gastrin levels
are elevated. 3 7 Pyloroplasty will partially
attenuate the postcibal response. 1 9 9 Similar
postcibal elevations have been observed in
patients given atropine. 2 0 0 It has been stated
that complete vagotomy will prevent the
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gastrin secretory response to insulin hypo
glycemia201' 202 but the consensus of the
available literature is that this statement is
incorrect.37 Gastrin release during insulin
hypoglycemia persists following complete
vagotomy.37- 100 Continued gastrin secre
tion may be related to gastrin release via
adrenergic influences.13' 36
After partial gastrectomy and gastrojejunal anastomosis (Billroth II) basal, and par
ticularly postcibal, gastrin levels are dimin
ished. On the other hand, partial gastrec
tomy and gastroduodenal anastomosis (Bill
roth I) affects the gastrin levels only slight
ly,203 suggesting continued release of duo
denal gastrin.
The relationship between recurrent ul
ceration and postoperative gastrin levels has
not been elucidated but when additional
data are available, ulcer surgery may be
come more rational.
Zollinger-Ellison Syndrome and AntralG-Cell Hyperplasia
Isenberg, Walsh and Grossman204 have
recently published an excellent review of
ZES. The disease is due to hypergastrinemia
and the big and heptadecapeptide forms of
gastrin account for the majority of the
serum and tumour gastrin.31' 205 As ori
ginally described, the syndrome included
fulminant peptic ulcer disease, gastric hy
persecretion and a non-y3-cell tumour of
the pancreas, but the clinical spectrum may
include moderate to severe peptic ulcer
disease, diarrhea, steatorrhea, vitamin B12
malabsorption and type I multiple endocrine
adenomatosis.
With the discovery of hypergastrinemia
with antral-G-cell hyperplasia (AGCH) as
well as with pancreatic and duodenal
gastrinomas the diagnostic work-up of ZES
has been expanded. AGCH was originally
described as ZES type I, with the classic
form being called type II, but it is now
clear that the two disorders are quite dis
tinct and can be separated by biochemical
and histologic criteria (Table V I I I ). 20°. 2 0 7
A differential diagnosis based on clinical
grounds, gastric acidity studies or fasting
gastrin levels is fraught with difficulties,
and the diagnosis is best established on the
basis of elevated gastrin levels after infu
sions of calcium, secretin or glucagon in
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ZES and elevated gastrin levels after food
in AGCH.207
Experience has shown that treatment for
ZES should consist of total gastrectomy,
the sole exception being an isolated duo
denal gastrinoma (although metastases may
be occult). Regression of metastatic tumour
has been reported after total gastrectomy.
If AGCH can be diagnosed accurately then
antrectomy should be curative.207- 208
WDHA Syndrome
Watery diarrhea, hypokalemia and achlor
hydria (WDHA syndrome, pancreatic chol
era, Verner-Morrison syndrome) have been
described with non-jS islet cell tumours200
and retroperitoneal tumours.123 Achlor
hydria is not invariable and the gastric
acidity studies may be normal. The diar
rhea may be cyclic or chronic. Other fea
tures of the syndrome may include hyper
calcemia, dehydration, hypokalemic nephro
pathy, metabolic acidosis, flushing and glu
cose intolerance (possibly due to hypokale
mia). The patients tend not to have a fam
ily history of endocrinopathy.
The hormone or hormones responsible
have not been identified with certainty but
must stimulate intestinal secretion while in
hibiting gastric secretion. Suggested pos
sibilities are secretin,209 G1P,116 V IP,112
prostaglandins,134 gastrin plus glucagon210
and a “CCK-like” hormone.211 At present,
if the syndrome is a single entity (which it
may not be), VIP is the most likely hor
mone responsible for the symptomatology.
Surgery is the treatment of choice, but
50% of the tumours are malignant and
the majority will have metastasized by the
time of surgery. Adrenocorticotropic hor
mone (ACTH) and steroid therapy have
been beneficial in controlling the diarrhea
of inoperable patients.209
TABLE VIII.—Antral-G-Cell H yperplasia
Zollinger-E llison Syndrome
Features

AGCH

Fasting gastrin
High
Gastrin release by food
Yes
Gastrin release by
secretin
No
Antral G cells
Hyperplasia
Pancreatic D cells
Normal
Tumour

No

v.

ZES

Very high
No
Yes
Normal
Hyperplasia
or
tumour
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Alimentary Hypoglycemia
Postprandial hypoglycemia in the ab
sence of pituitary, adrenal and liver dis
ease or early diabetes is almost invariably
of alimentary origin. Patients with rapid
gastric emptying (either primary or sec
ondary to gastric surgery) or enhanced glu
cose absorption frequently develop alimen
tary hypoglycemia. Postprandial hypogly
cemia has also been described in patients
with no obvious intestinal defects.151 The
pathogenesis involves several nonexclusive
variables including blood sugar, insulin
secretion and enteroglucagon levels.
Although early hyperglycemia is common,
it is not essential for the development of
hypoglycemia.149 Likewise, hyperinsulinemia may also be absent.212 Hyperenteroglucagonemia is a frequent finding.105
The pathophysiology probably involves
varying combinations of hyperinsulinemia
(secondary to hyperglycemia and incretin)
and hyperenteroglucagonemia, which may
inhibit the effects of pancreatic glucagon.105
Therapy involves the use of small, iso
caloric, low carbohydrate meals to reduce
hyperglycemia and to reduce induction of
incretin149 and enteroglucagon, antichol
inergics to delay gastric emptying, and small
doses of phenformin (50 mg) to reduce
glucose absorption and incretin secre
tion.150, 151
Irritable Bowel Syndrome
Many of the patients seen by gastroen
terologists are afflicted by the irritable bowel
syndrome,213 a complex disorder of ab
normal esophageal, small intestinal214 and
colonic function.215 The disorder is rightly
called a syndrome and probably represents
the interaction of psychic, environmental,
dietary and GI influences. The role of GI
hormones in the pathogenesis of the dis
order is not fully defined but Harvey and
Read216 have recently demonstrated colonic
motility disturbances and reproduction of
symptoms during infusions of CCK in pa
tients with the irritable bowel syndrome.
Similar disturbances have been documented
following presumed CCK release after oral
magnesium sulfate administration.178 These
experimental results and the clinical ob
servation that symptoms frequently follow
the ingestion of food suggest, very strongly,
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that in some patients the irritable bowel
syndrome may be secondary to disordered
GI endocrinology. It is not yet known
whether these patients are overproducing
hormones or are just overly sensitive to
normal hormone levels.
Study in the field of gastrointestinal endo
crinology began over 70 years ago with the
discovery of secretin by Bayliss and Starling.
Interest in this field has grown rapidly in
the last decade. In this review I have at
tempted to summarize the current state of
knowledge in gastrointestinal endocrinology
and to indicate the relevance of this knowl
edge to certain diseases of man. Much is
still to be discovered.
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SEL F-A SSE SSM E N T
SESAP II QUESTION
507. Which of the following statements concerning serum gastrin levels is/are correct?
(1) They can be measured by radioimmunoassay using gastrin labeled with iodine-125
(2) They usually increase markedly in patients who have had antrectom y and vago
tomy
(3) They are useful in identifying patients with the Zollinger-Ellison syndrome
(4) They are useful in investigating the possibility of residual vagal function after va
gotomy
For this question one or more of the answers given above is correct. Y our answer should be:
A
B
C
D
E

if
if
if
if
if

only 1, 2 and 3 are correct,
only 1 and 3 are correct,
only 2 and 4 are correct,
only 4 is correct,
all are correct.

For the critique of Item 507 see page 372 of this issue.
(Reproduced by permission of the American College of Surgeons from SE SA P II Syllabus:
Surgical Education and Self-assessment Program No. 2.)

END-TO-SIDE ANASTOMOSES OF VEIN GRAFTS TO ARTERIES*
S. E. CARROLL, MD, FRCS[C], FACS

A lthough Linton1 described the use of a
small venous tributary in the acute angle of
end-to-side anastomoses between a vein
graft and artery, I have found a larger tribu
tary of greater length more convenient. If
short transverse limbs, proximally and distally, are added to the arteriotomy,2 a rec
tangular anastomosis may be fashioned,
helping to fix the intima (Fig. 1). This is
particularly important in maintaining flow
in both directions, for example, in the dis
tal popliteal artery, below the origin of the
anterior tibial branch. A larger venous tribu
tary used in this way allows the surgeon to
fashion the distal anastomosis with less risk
of narrowing of the vein graft at the junction
and gives extra length when this is crucial.
Occasionally a tributary may be used at the
distal end of the anastomosis, but in this
situation the surgeon must be careful to re
move valve tissue that may obstruct flow.
With ingenuity a suitable tributary can al
most always be found.

VEIN

GRAFT

OPENED

Fig. 1.—End-to-side anastomosis, (a) Method
of removing long saphenous vein (LSV) with
tributary, (b) Opening proximal vein into tribu
tary. (c) Variations in arteriotomy. (d) Completed
rectangular anastomosis.

R eferences

*From the department of surgery, St. Joseph’s
Hospital, London, ON.
Reprint requests to: Dr. S. E. Carroll, Chief of
surgery, St. Joseph’s Hospital, 268 Grosvenor
St., London, ON N6A 1Y6.

1. L inton RR: Atlas of Vascular Surgery, Phila
delphia, Saunders, 1973, p 464
2. Barker WF: Peripheral Arterial Disease,
Philadelphia, Saunders, 1966, p 139
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D A V ID A. E. SHEPHARD
This journal is one of countless S U R G IC A L
JOURNALS published throughout the world.
All have useful functions, and there are as many
different types o f surgical journals as there
are functions and editors shaping them. A s
varied and as numerous as these journals are,
however, their origin can be traced to one
progenitor — Philosophical Transactions —
just as the many antibody-secreting lym pho
cytes develop from one cell type. The history
of surgical journals well illustrates this series’
theme that surgeons’ nonsurgical colleagues
have always shaped important developments in
surgery.
The key developments in the history o f sur
gical journals were these. In 1455, Gutenberg,
in making available movable type, facilitated
the spread o f scientific knowledge. Dur
ing the 16th and 17th centuries, many natural
philosophers began to advocate the scientific
method of enquiry and the direct observation
of nature: Bacon advised his colleagues to
“read not to contradict and confute, nor to
believe and take for granted . . . but to weigh
and consider” ; and Descartes recommended
“the methodic doubt of everything” . Soon the
importance o f a single experiment or observa
tion was recognized; books could no longer
serve as means o f rapid dissemination; corre
spondence among scientists then assumed the
function o f speedy communication; however,
letters were laborious to write in any number
and, out o f fear that they might too readily be
criticized, letters tended to be sent to col
leagues who would be unlikely to reject their
content, which hardly served the Baconian
method. So the idea that letters be printed and
published periodically arose, an idea that re
stored the principles behind scientific com m u
nication and also led to the development of
the scientific periodical. The Transactions were
first published in 1665. It was the first truly
scientific journal and became the model for
those that followed.
Scientific journals soon began to proliferate;
they continue to do so. Their objective, how
ever, has remained the sam e: today’s readers,
among whom are innumerable surgeons, share
the thinking o f the president of the Royal
Society in 1661, Robert M oray, who realized
the importance o f “communication among us
of whatever knowledge m ay further for pos
terity . . . most necessary o f studies”.
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EFFECTS OF AMBIENT AND STAGNANT HYPOXIA ON THE
MECHANICAL AND ELECTRICAL ACTIVITY
OF THE CANINE UPPER JEJUNUM*
A. MEISSNER, M D ,t K. L. BOWES, MD and S. K. SARNA, PhD!
The effects of ambient and stagnant hypoxia on
the mechanical and electrical activity of the
upper jejunum were studied in 32 anesthetized
dogs. A 50 or 7 5 % reduction in oxygen content
of inhaled air produced ambient hypoxia; su
perior mesenteric artery (S M A ) occlusion or
thrombin-induced mesenteric thrombosis resulted
in stagnant hypoxia. Induction of hypoxia was
immediately followed by a transient increase
in mechanical activity. A 5 0 % reduction in oxy
gen content had no other effect. A 7 5 % reduc
tion in oxygen content resulted in a gradual
decrease in electrical control activity (ECA) fre
quency and in the disappearance of electrical
response activity (ERA), and in jejunal contrac
tions; however, ECA persisted until cardiac ar
rest occurred after 30 to 45 minutes of hypoxia.
Occlusion of the S M A resulted in a significant
decrease in contractile activity but ECA was not
affected. Thrombin-induced mesenteric throm
bosis produced rapid and irreversible disappear
ance of both electrical and mechanical activities.
Jejunal con.ractions and ERA are dependent
upon an adequate oxygenated blood supply. ECA
however, is highly resistant to reduction in oxy
gen content of perfused blood and continues
until perfusion stops.
Les effets de I'hypoxie ambiante et stagnante
sur les activites mecaniques et electriques du
jejunum superieur ont ete etudies chez 32 chiens
anesthesies. line diminution de 50 a 7 5 % de la
teneur en oxygene de I’air inhale a produit I’hypoxie ambiante. L’occlusion de I’artere mesenterique superieure (A M S) ou la thrombose mesenterique provoquee par la thrombine ont resulte en
*From the department of surgery and SurgicalMedical Research Institute, University of Alberta,
Edmonton, AB.
Presented at the annual meeting of the Royal Col
lege of Physicians and Surgeons of Canada, Que
bec City, Que., January 21, 1976.
Supported by the Medical Research Council of
Canada.
1 Edmonton civic employees’ surgical research fel
low. Present address: Institute of Hematology, D e
partment of surgery, 00957 Warsaw, Poland,
Chocimska nr. 5.

tPresent address: Department of surgery, Mcmaster University, Hamilton, ON.
Reprint requests to: Dr. K. L. Bowes, 11-117
Clinical Sciences Building, University of Alberta,
Edmonton, AB T6G 2G3.

une hypoxie stagnante. L'induction de I'hypoxie a
immediatement ete suivie d’une augmentation
transitoire de I'activite mecanique. Une baisse
de 5 0 % de la teneur en oxygene n’a produit
aucun autre effet. Une diminution de 7 5 % du
contenu en oxygene a entraine une baisse graduelle de la frequence de I'activite de contrdle
electrique (ACE), et la disparition de I'activite
de reponse electrique (ARE) et des contractions
jejunales. Toutefois, I’ACE s ’est maintenue jusqu'a I'arret cardiaque qui est survenu apres 30
a 45 minutes d’hypoxie. L’occlusion de I'A M S a
entraine une diminution significative de I’activite
contractile mais I'A C E n'a pas ete affectee. La
thrombose mesenterique provoquee par la
thrombine a produit la disparition rapide et ir
reversible, a la fois, des activites electriques
et mecaniques. Les contractions du jejunum et
I'ARE sont trse dependantes d'une reserve san
guine adequate en oxygene. L’AC E cependant,
est tres resistante a une diminution de la teneur
en oxygene du sang de perfusion et persiste
jusqu'a I'arret de la perfusion.

Two types of electrical activity can be
recorded from the small bowel muscle of
dogs and humans.1 The first, electrical con
trol activity (ECA) (slow waves, pacesetter
potential), is omnipresent and has a maxi
mum frequency of 18 cycles/min in the
duodenum of the dog. It controls the ap
pearance in time and space of a second
type: electrical response activity (ERA)
(fast activity, spike potential). ERA initiates
mechanical activity; that is, whenever ERA
occurs at a site, the muscle at that site con
tracts. ECA in the small bowel of the dog
results from bidirectionally coupled relaxa
tion oscillators.2
It has been suggested that ERA and ECA
could determine the viability of bowel at
laparotomy.3- 4 Ligation of mesenteric ves
sels in the dog results in rapid disappear
ance of both types of small bowel electrical
activity. However, bowel ischemia may oc
cur clinically in low-flow or hypoxic states
without occlusive vascular disease.5 The re
lative importance of flow and hypoxia in
the generation of electrical activity is not
known.
In this study, in attempting to determine
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the relative importance of flow and oxyge
nation in the generation of electrical and
mechanical activities of the small bowel, we
compared the effects of ambient and stag
nant hypoxia on small bowel electrical and
mechanical activity in three groups of dogs.
M ethods

Anesthesia
Adult, healthy dogs (weight, 15 to 20
kg) were fasted for 16 hours before each
experiment. After induction of anesthesia
with intravenous sodium pentobarbital (30
mg/kg body weight) the dogs were intu
bated with a plastic tube. To initiate con
trolled respiration, succinylcholine chloride
(30 mg) was administered intravenously, and
the endotracheal tube connected to a res
pirator. The dogs were ventilated 14 times/
min with 80% nitrogen and 20% oxygen
at a tidal volume of 15 m l/kg body weight.
Partial pressure of oxygen (Po2) in the
inhaled gas mixture was equal to that of
room air. Anesthesia was supplemented by
sodium pentobarbital (10 mg/kg) and suc
cinylcholine chloride (20 mg) as required.
Preparation of Jejunum and Monitoring
of Jejunal Activity
At laparotomy a loop of upper jejunum
was exposed and three bipolar silver wire
electrodes6 were implanted subserosally
every 10 cm and oriented transversely to the
bowel axis. The first pair of electrodes was
placed 30 cm caudad to the ligament of
Treitz. Contractile activity of the small
bowel was recorded by extraluminal force
strain gauges (R.B. Products, 153 Nautilus
Dr., Madison, WI) aligned with the trans
verse axis of the small bowel and sutured
to the serosal surface at 10-cm intervals.
The first was attached 3 cm distal to the
first bipolar electrode. Recordings were
made on an eight-channel Beckman R411
dynagraph recorder. The myoelectric signals
were filtered with upper and lower cut-off
frequencies at 22 Hz and 1.6 Hz, respec
tively.
Production of Ambient and Stagnant
Hypoxia
Group 1.— Ambient hypoxia was pro
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duced in this group by reducing the oxygen
content of inhaled air by 50% (seven dogs)
or 75% (seven dogs). Partial pressures of
arterial and inhaled gas were determined
before and every 30 minutes after oxygen
reduction. The 50% reduction in oxygen
lasted for 2 hours and the 75% reduction
until cardiac arrest occurred. A continu
ous recording of small bowel electrical and
mechanical activity was made for 1 hour
before and 2 hours after establishing am
bient hypoxia.
Group 2.— In this group of nine dogs
stagnant hypoxia was produced by occlud
ing the superior mesenteric artery (SMA)
for 2 hours by tightening a hemostatic
snare, in the form of a polyethylene tube
(ID, 0.86 mm; OD, 1.27 mm), placed
around the vessel. The distal branch
of the SMA was isolated (50 cm
caudad to the ligament of Treitz) and cannulated with an identical polyethylene tube,
whose tip was positioned in the main trunk
of the SMA. The femoral artery was then
exposed and cannulated with a polyethylene
tube (ID, 1.67 mm; OD, 2.41 mm). Each
tube was connected to a transducer and
hence to the recorder. Systematic and SMA
blood pressures were recorded during the
experiment. A decrease in blood pressure
recorded in the distally placed polyethylene
tube was interpreted as proof of SMA oc
clusion (stagnant hypoxia). Electrical and
mechanical activities were recorded for 1
hour before, during the 2-hour period of
artery occlusion, and for 1 hour after re
lease of the snare.
Group 3.— In five dogs stagnant hy
poxia was produced by direct injection of
thrombin topical (150 N IH units/kg body
weight; supplied by Parke-Davis & Co.
Ltd., Montreal), which produced vein and
SMA thrombosis. During the infusion (30
to 60 s) the SMA and vein were occluded.
Electrical and mechanical activities were
recorded for 1 hour before and 2 hours
after thrombin injection. Full-thickness seg
ments of the intestinal wall were examined
histologically at the end of the experiments.
To complete the experimental prepara
tion, the small bowel was replaced in the
peritoneal cavity, the laparotomy wound
was closed, and the connecting wires and
tubes were brought out through the suture
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line. Monitoring of the respiratory action
throughout the study was by a transducer
connected by a polyethylene tube to the
respirator. A continuous electrocardiographic
recording was made.
R esu lts

We recorded two types of electrical activity
from the upper jejunum — electrical con
trol activity (ECA) and electrical response
activity (ERA) (Fig. 1).
In the 1-hour basal period, ECA in all
dogs was phase-locked' with an aboral di
rection of phase lag and a mean frequency
of 17.3 ± 0.91 cycles/min ( ± SEM). Re
sponse activity was usually noted when con
tractions appeared, but, as the positions of
electrodes and strain gauges were not ident
ical, exact correlation did not always oc
cur.
We recorded two patterns of contractile
activity with the extraluminal force trans
ducers,* the first consisting of groups of
repetitive low-amplitude contractions ap
pearing 4.8 ± 0.45 times per 5-minute re
cording period (total duration, 56.0 ± 6.22
s), and the second consisting of groups of
high-amplitude repetitive contractions ap
pearing 2.5 ± 0.31 times per 5-minute re
cording period (total duration, 140 ± 16.1
s).
Effects of Ambient Hypoxia (Group 1)
In all dogs, a 50% decrease in oxygen
content of inhaled mixture (Po2, 67.5 mm
Hg) resulted in a decrease in arterial Po2
from 61.6 to 35.9 mm Hg. A 75% re
duction in oxygen content of inhaled air
(Po2, 37.4 mm Hg) resulted in a decrease
in arterial Po2 from 66.7 to 16.8 mm. Hg.
Immediately after 50 and 75% reduction
of oxygen in inhaled air, there were highamplitude repetitive contractions (mean
*Quantitation of mechanical activity as recorded
by external force transducers is difficult. Although
ex-vivo quantitation of transducers is possible, the
tension under which the gauge is sutured, the
depth of sutures, slight deviations from the trans
verse axis, and the state of bowel when the trans
ducer is applied all profoundly influence their
sensitivity. These factors obviate the extrapolation
of ex-vivo results to the in-vivo situation. For the
purpose of this investigation we arbitrarily clas
sified mechanical activity into low amplitude
« 1-cm deflection) and high amplitude (> 1-cm
deflection).
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Fig. 1.—Types of electrical and mechanical ac
tivity of upper jejunum during control period.
Mechanical activity (SG1-SG3) appeared intermit
tently either as groups of repetitive low-amplitude
contractions (early part SGI) of repetitive highamplitude (SG1-SG3) contractions. ECA (El - E3)
appeared regularly 17.3 ± 0.91 times/min. ERA
(early part E1-E3) was intermittently super
imposed on ECA. Electrodes and strain gauges are
at different positions (see text) so ERA and con
tractions do not exactly correspond.

duration, 4.8 ± 0.33 min). ERA was as
sociated with the contractions but ECA did
not change.
Following the transient increase in me
chanical activity and ERA, the patterns and
frequencies of electrical and mechanical ac
tivities in dogs subjected to a 50% reduction
in inhaled gas oxygen content rapidly re
turned to control levels. Systemic blood
pressure did not change appreciably during
hypoxia or after.
The 75 % decrease in inhaled oxygen con
tent resulted in a progressive decrease in ECA
frequency from 17.1 ± 0.47 cycles/min to
11.9 ± 1.72 cycles/min 30 minutes after
oxygen decrease (P < 0.05) (Fig. 2); ECA
was, however, continuously present and
phase-locked in an aboral direction, though
at a lower frequency, until the heart stopped
or fibrillated 42 ± 5.37 minutes after 75%
oxygen decrease (Fig. 3). Systemic blood
pressure was maintained until the heart
slowed or its rhythm became irregular.
After the initial transient increase in con-
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Fig. 2.—Mean ECA frequency before (C) and
after either oxygen reduction or occlusion of the
superior mesenteric artery (SMA). Vertical lines in
dicate ± SEM. Arrow indicates release of occlu
sion or reestablishment of normal oxygen level in
inhaled air. X indicates recorded values 10 to 15
minutes before arrest of heart action.

tractile activity, low- and high-amplitude
contractions and ERA disappeared. ERA
and contractions were absent for the re
mainder of the experiment.
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Fig. 3.—Electrical and mechanical activity of
jejunum at time of circulatory arrest after 75%
reduction in oxygen content of inhaled air. Note
absence of contractile activity and persistence of
ECA until moment of arrest.
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Effects of SMA Occlusion (Group 2)
Traction on the plastic tube placed
around the SMA produced a striking de
crease in blood pressure within its branches.
Throughout the occlusion period, however,
the mean blood pressure in the SMA re
mained at 15 to 20 mm Hg. Immediately
after occlusion there were high-amplitude
repetitive contractions associated with ERA
for 3.5 ± 0.75 minutes. ECA did not
change. After this brief interval of increased
contractile activity, there was a period of
diminished activity that persisted to the end
of the experiment (Fig. 4). Low-amplitude
repetitive contractions were less common,
appearing 2.5 ± 0.44 times per 5-minute
period (P < 0.05). High-amplitude repetitive
contractions diminished slightly but not sig
nificantly from a basal incidence of 2.7 ±
0.57 to 1.3 ± 0 .4 4 times per 5-minute
period. The total duration of the high-am
plitude contractions, however, increased
from 110.4 ± 21.3 to 210.1 ± 18.2 seconds
(P<0.05). Throughout the experiment ECA
remained phase-locked in an aboral direction
with a frequency of 16.8 ± 0.31 cycles/min.
After release of tape around the SMA
and restored full blood flow, contractile ac
tivity Returned to the pattern seen in the
control period.
Effects of SMA and Vein Thrombosis
(Group 3)
Direct administration of thrombin into
the SMA produced intravascular coagula
tion in all small-diameter arteries and capil
laries of the small bowel and in all tribu
taries of the superior mesenteric vein. The
small bowel became cyanotic and hemor
rhagic. There were diffuse subserosal and
submucosal hemorrhages with extravasation
of blood into the small bowel lumen.
A transient period (2.3 ± 0.24 min) of
high-amplitude repetitive contractions im
mediately followed the thrombin injection.
Then contractile activity and ERA disap
peared and were not recorded again (Fig. 5).
In four dogs ECA disappeared 6.5 ± 0.91
minutes after thrombin injection but in one
it ceased 45 minutes after mesenteric throm
bosis. ECA remained phase-locked and the
direction of the phase lag was always aboral
until it ceased.
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30 MIN AFTER

Fig. 4 .—Mechanical activity of jejunum before and 30 minutes after occlusion of SMA.
D is c u s s io n

In this study ambient hypoxia produced
by decreasing the oxygen content of inhaled
air caused a transient increase in jejunal me
chanical activity. When the oxygen reduc
tion was minor (50%), normal contractile
activity rapidly returned. When the oxy
gen reduction was greater (75%), all me
chanical activity rapidly disappeared. Stag

nant hypoxia, produced in these experiments
by SMA occlusion, was also followed by
an initial transient increase in mechanical
activity. Thereafter, contractions persisted
at a greatly reduced rate. SMA pressure fol
lowing ligation persisted at 15 to 20 mm Hg
indicating the presence of substantial col
lateral circulation through the pancreatico
duodenal arcade.
Throughout all of the procedures ECA

RESP.

Fig. 5.—Jejunal electrical and mechanical activity before and after massive intravascular coagu
lation produced by injection of thrombin into SMA.
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persisted and remained phase-locked in an
aboral direction. Only after a 75% decrease
in oxygen content of inhaled air did the
frequency decrease. Even then ECA per
sisted until all flow ceased at the time of
cardiac arrest. When the injection of throm
bin into the SMA produced rapid cessation
of flow ECA, ERA and all mechanical ac
tivity disappeared.
The persistence of ECA until the com
plete arrest of circulation indicates that it is
comparatively resistant to hypoxia. ECA is
primarily a myogenic function and does
not require nervous or hormonal input for
its generation. It is dependent upon the
integrity of the cellular sodium pump.7
Upon complete arrest of blood flow, rapid
changes in cell membrane permeability, elec
trolyte concentration, and metabolite accu
mulation occurred. These changes probably
resulted in the disappearance of ECA.
Mechanical activity, on the other hand,
appears to be more sensitive to changes in
arterial Po2. It is difficult to attribute such
rapid changes to neural degeneration; they
are more likely due to changes in mem
brane permeability produced by hypoxia.
It has been suggested4 that the recording
of electrical activity at operation may be of
value in determining the viability of bowel
in low-flow states and after arterial or
venous thrombosis and embolism. Recording
at the time of operation, however, may be
misleading. This study indicates that a
normal jejunal ECA frequency can persist
in spite of severe hypoxia. In addition,
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small bowel ischemia may progress
following laparotomy. It has been suggested
that all patients operated on for ischemic
bowel disease have a second laparotomy 24
hours later to check for progression of the
ischemia. The use of electrodes implanted
into the small bowel with recording in the
postoperative period in such patients may
obviate the need for a second operation.
Electrodes have been implanted into the
stomach of patients undergoing laparotomy
by Sarna, Bowes and Daniel6 without side
effects. The clinical application of small
bowel electrical activity recording in ische
mic bowel disease may take this form.
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MALADIE DE PAGET DU SEIN CHEZ L’HOMME
M AURICE FALARDEAU, MD, FRCS[C],* MLADEN RUSNOV, MD, FRCS[C1+
et ROBERT LESAGE, MD, FRCP[C]i
Un homme de 78 ans se presente pour une maladie de Paget du sein. II s’agit d’une entite
rare et nous croyons presenter le 22eme cas
prouve histologiquement bien qu'en 100 ans
environ 40 articles et moins de 50 observations
aient ete publies.
A la lumiere de I’experience recente, les au
teurs ont opte pour une chirurgie plus limitee
soit une mastectomie totale avec evidemment
axillaire plutot qu’une mastectomie radicale classique puisqu'il n'y avait ni masse sous-jacente
cliniquement decelee ni adenopathie.
De plus, retenons que toute lesion eczematoide du mamelon qui persiste plus de 2 semaines ou qui est u n ila te ra l devient suspecte
de malignite et devrait alors etre biopsee.
t
The case of a 78-year-old man with Paget's dis
ease of the breast, described herein, appears to
be only the 22nd histologically proven case of
this rare condition; in over 100 years less than
50 cases have been reported. Since this patient
had no underlying tumour or nodal involvement
the operation consisted of total mastectomy
with removal of axillary nodes only, rather than
the classical radical mastectomy. All eczematoid
lesions of the areola of the breast that persist
for more than 2 weeks or are unilateral should
be considered Paget’s disease until proven
otherwise by biopsy.

E n 1874 Sir John Paget1 a decrit pour la
premiere fois la maladie de Paget du sein.
La description de Paget s’ajoutait a l’observation de Velpeau de 1859 mais, selon
Sekigughi,2 c’est Erichsen qui, en 1879,
proposat que cette entite porte le nom de
maladie de Paget. Nous rapportons un cas
de cette affection chez Fhomme.
Affection peu frequente, puisque le can
cer de la glande mammaire est environ 100
fois plus rare chez le sexe masculin que
*Professeur agrege, departement de chirurgie, Uni
versity de Montreal. Membre actif senior, Hopital
Notre-Dame, Montreal, PQ.
tEx-resident en charge, departement de chirurgie,
Hopital Notre-Dame, Montreal.
tProfesseur adjoint de clinique, departement de
pathologie, Universite de Montreal. Membre actif
senior, Hopital Notre-Dame, Montreal.
Les demandes de tires-a-part doivent etre adressees au: Dr. Maurice Falardeau, departement de
chirurgie, Hopital Notre-Dame, 1560, rue Sher
brooke, est, Montreal, PQ H2L 4M1.

chez le sexe feminin3"6 et que la maladie
de Paget constitue de 1 a 3% de tous les
cas de neoplasie mammaire,4’ 7- 8 on s’attend a trouver un homme atteint de cette
maladie sur 3 a 10 000 cas de cancer du
sein. Au Centre d’Oncologie de l’Hopital
Notre-Dame, sur 5076 cas de neoplasie du
sein qui ont ete observes sur une periode
de 32 ans, on compte 7 femmes atteintes
de maladie de Paget et seulement 2 hom
ines. Un de ces cas a ete opere initialement
ailleurs et nous rapportons ici le second.
En 100 ans, environ 40 articles et une
quarantaine d’observations ont ete publies
dans la litterature mondiale sur ce sujet.
Toutefois, selon Crichlow et Czernobilsky,4
seulement 11 cas authentiques auraient ete
decrits jusqu’en 1969. Ces auteurs en ont
rapporte deux autres, auxquels viennent
s’ajouter les cinq cas de Coley et Kuehn9
et d’autres publies par Suzuki et Kubota,10
Von Bartel et Wagner,11 O’Grady et McDivitt," Nance et collegues,8 et Haagensen.12 Enfin, celui que nous presentons ici,
serait done le 22eme.
P r e s e n t a t io n C l in iq u e

Un homme, age de 78 ans, est admis dans
le service d’opthalmologie en mars 1974. Entre
1961 et 1969, il avait ete hospitalise a quatre
reprises pour un infarctus du myocarde, une
periarthrite de Fepaule droite, une cholecystite
et une cataracte. En aucun moment, il ne fut
mention de lesion au sein.
A l’examen physique, on decouvre une le
sion squameuse du sein droit. En retrospective,
le malade raconte que, depuis une dizaine d’annees, il accuse localement un prurit modere
et que le mamelon saigne en certaines occa
sions.
Le dermatologiste consulte note une plaque
erythemateuse, bien delimitee, squameuse, interessant tout le mamelon droit, sans adherence
au plan profond, mesurant environ 3 cm de
diametre (Fig. 1); il n’y a pas de masse sousjacente. Aucun ganglion axillaire n’est palpe.
Le sein gauche est normal.
La mammographie ne decele ni gynecomastie ni lesion tumorale et l’etude radiologique du
squelette ne montre aucun signe de metastase
osseuse. On procede alors a une biopsie qui
demontre une maladie de Paget du sein. Le
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L’evolution postoperatoire est normale et 28
mois plus tard le malade est asymptomatique.
D isc u ssio n

Fig. 1.—Aspect clinique d’une maladie de Paget.

malade subit ensuite une mastectomie simple
(totale) avec evidemment ganglionnaire axillaire.
Le specimen anatomo-pathologique nous
montre un fragment provenant du mamelon ou
l’epiderme est infiltre par de larges cellules a
cytoplasme clair avec des noyaux irreguliers
et parfois mitotiques (Figs. 2 et 3). Au niveau
de la glande mammaire sous-jacente, on note
des canaux remplis par une proliferation de
cellules epitheliales neoplasiques. II n’y a pas
d’envahissement extracanaliculaire (Fig. 4). II
n’y a pas de metastase au niveau des ganglions
axillaires.

Sur le plan clinique, le symptome le plus
frequent de la maladie de Paget du sein
est l’ecoulement du mamelon avec excoria
tion et ensuite ulceration. Le malade se
plaint la plupart du temps d’un prurit leger.
On retrouve un eczema du mamelon et de
l’areole avec ou sans masse sous-jacente et
l’envahissement ganglionnaire est rare chez
1’homme. Sur les 13 cas colliges par
Crichlow et Czernobilsky,4 9 presentaient
une masse et 5 seulement avaient une atteinte des ganglions.
Les changements cutanes precedent-ils
l’apparition de la neoplasie ou en sont-ils
une manifestation secondaire? Treves13 en
1954 rapporte un cas ou la maladie est
demeuree localisee a la peau pendant 14
ans sans qu’on n’ait pu deceler d’epithelioma
de la glande ni de metastase ganglionnaire
lors de la mastectomie. Des delais de 25 et
30 ans ont ete rapportes respectivement par
Sekigughi2 et Fabry et Trautm ann.2
De plus, selon Dockerty et Harrington14
et Coley et Kuehn,9 on peut retrouver une

Fig. 2.—Envahissement de l’epiderme par des cellules de Paget (hematoxyline et eosine; le grossissement fx 1601 a ete reduit de 25%).
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Fig. 3. Cellules de Paget (hematoxyline et eosine; le grossissement [x 4001 a ete reduit de 25%).

maladie de Paget du mamelon a un stade
pre-clinique, sans lesion eczemateuse macroscopique du mamelon mais avec des cel
lules de Paget typiques a 1’histologie.
Enfin une maladie de Paget du sein doit
toujours faire rechercher attentivement une

neoplasie mammaire sous-jacente a la le
sion du mamelon.
En pratique toute lesion eczematoide ou
excoriation du sein qui persiste plus de 2
semaines doit faire 1'objet d’une biopsie.
On doit considerer toute lesion unilateral

Hg. 4.—Proliferation neoplasique bien localisee a l’interieur des canaux galactophores (hematoxy
line et eosine; le grossissement [x 160] a ete reduit de 25%).
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comme une maladie de Paget jusqu’a preuve
du contraire. La mammographie constitue un
adjuvant precieux pour deceler la presence
ou Fabsence d’une masse sous-jacente.
Le diagnostic differentiel est a faire avec
la maladie de Bowen, l’adenomatose benigne du mamelon, Feczema simple, la folliculite, le melanome amelanique, la croute
banale de Fhygiene defectueuse et la neoplasie ulceree du sein envahissant le ma
melon.
Sur le plan histopathologique, la maladie
de Paget consiste en une infiltration de l’epiderme par de larges cellules a cytoplasme
clair dites cellules de Paget mais decrites
par Darter15 en 1889 et le diagnostic definitif depend de la presence de ces cellules de
Paget.
Ceci nous amene a etudier la relation
entre les changements epidermiques du ma
melon et le cancer du sein sous-jacent. II
s’agit d’un envahissement de l’epiderme par
des cellules neoplastiques d’origine canaliculaire.4 Les cellules tumorales envahissent
progressivement les canaux galactophoriques
puis l’epiderme de surface.
Le traitement de cette maladie est des
plus controversy. Jusqu’a recemment, seule
la mastectomie radicale avec greffe3’ 10- 13,
16 cutanee etait acceptee comme traitement
valable. Des articles tout recents mettent en
doute cette assertion.12’ 17
La rarete de cette lesion chez Fhomme
interdit en fait d’adopter une attitude rigide.
Dans Fobservation que nous rapportons
ici, le patient n’a subi qu’une mastectomie
totale avec evidemment axillaire. Selon les
resultats histologiques, il semble bien qu’il
n’y avait pas d’indication de faire davantage
puisque les ganglions axillaires preleves
etaient indemnes d’envahissement.
D’une fa?on generate, le pronostic d’un
cancer du sein chez Fhomme serait moins
bon.18’ 19 Le milieu hormonal male en
serait-il responsable? Les hommes consulteraient-ils apres un plus long delai? Enfin
le sein de Fhomme etant plus petit, l’envahissement des structures avoisinantes se ferait-il plus rapidement?
Holleb, Freeman et Farrow17 croient que
le pronostic a pu sembler moins bon parce
que tres peu de neoplasies du sein sont
observees chez Fhomme et que les referen
ces valables sont encore plus rares.
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Nous croyons que la maladie de Paget
avec masse palpable ne differe que tres peu
des autres cancers du sein et doit etre traitee
comme tel. Cependant, si la presence d’une
tumeur ne peut etre decelee dans le sein ni
cliniquement ni a l’aide de la mammogra
phie et si l’extension de l’erosion du ma
melon ne depasse pas l’areole, une mastec
tomie simple (totale) doit etre consideree
comme un traitement definitif, particulierement chez les patients avec un risque operatoire elevee.
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C o u rs e o f illn e s s

No.

%
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to reduce mortality in acute pancreatitis to a significant 4 !

P laceb0................................................ 25.0% Mortality
7.5% Mortality
Because the number of deaths were reduced, the spectrum of the disease
as a whole was altered.” *
Trasy |Ql®...................................................

Trapnell’s recent double-blind clinical trial
involving 105 patients confirmed the
effectiveness of Trasylol in acute
pancreatitis. In addition to reducing
mortality and altering the spectrum of the
disease, Trasylol largely abolished the usual
effect of increasing age in this condition.
Trasylol should be given concurrently with the
usual measures for the treatment of
pancreatitis, such as pain relief,
fasting, gastric suction, etc. “ It
(Trasylol) can therefore now be
regarded as a drug which is both
effective and beneficial in the
treatment of acute pancreatitis.” *
*Trapnell, J.E. et al, British
J. Surg., March 1974.

The Effect of

Trasylol
in
Hyperfibrinolytic
Hemorrhages

Trasylol, in its role as an
antifibrinolytic agent, inhibits
both plasmin and the
plasminogen activator.

Synthetic antifibrinolytic
agents inhibit only the
plasminogen activator.

Trasylol is indicated for prim ary and generalized, secondary
hyperfibrinolytic hem orrhages with and w ithout the shock
syndrom e. Secondary hyperfibrinolysis follo w in g
/ * * \ intravascular clotting may require heparin a n d /o r
fibrinogen replacem ent in addition to Trasylol.
W ith Trasylol, the antifibrinolytic agent w ith
sim ultaneous anti-coagulant (a nti-th rom bop lastic)
effect, there w ill not be a dangerous shift
in the equilibrium between
the clotting and the lysis system
in favour of coagulation.
Synthetic a n tifib rin o lytics
are contraindicated if there is
evidence of active intravascular
coagulation. Trasylol is indicated
in all cases of hyperfibrinolysis,
w hether a differential diagnosis
has been made or not.
FBA Pharmaceuticals Ltd.
Distributed by:
Boehringer Ingelheim (Canada) Ltd.
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Trasylol
• increases the chances
of survival in acute
pancreatitis
• prevents the enzymatic
release of toxic
polypeptides and kinins
• stops hyperfibrinolytic
hemorrhage
Indications and Dosage

Hyperfibrinolytic Hemorrhage
T h e s e c o n d itio n s o c c u r in s u rg e ry ,
including open heart surgery, prostatic
s u rg e ry and p a th o lo g ic a l o b s te tric a l
bleeding conditions, such as in abruptio
placentae.
Initial dosage: 200,000 — 500,000 K.I.U.
of w hich 200,000 K.I.U. should be given
by intravenous injection (a t a rate not to
exceed 5 ml per minute), the rest if neces
sary by slow in fu s io n . A d m in is tra tio n
sh o u ld be c o n tin u e d up to 1,000,000
K.I.U. per day until the hemorrhage has
been arrested.

Pancreatitis
Initial dosage: 100,000 — 200,000 K.I.U.
to be follow ed by 100,000 K.I.U. every
six hours fo r a period of 4-5 days. The
drug is adm inistered e ith e r by intraven
ous in je ctio n (at a rate not to exceed 5
ml per minute) or by slow infusion.

Warnings and Precautions
Trasylol is a polypeptide and thus may
act as an antigen. Although adverse reac
tions due to hypersensitivity have been
described infrequently, this possibility
should always be kept in mind. In patients
w ith a h isto ry of h y p e rs e n s itiv ity , the
usual precautions for the prevention and
a rre s t o f a lle rg ic re a c tio n s sh o u ld be
observed prior to the adm inistration of
Trasylol.

Availability
Trasylol (aprotinin) is available in 10 ml
a m p u ls c o n ta in in g 1 0 0 ,0 0 0 K .I.U . in
boxes of 5 ampuls.
Trasylol® Product Monograph is available
on request.

The object of

Trasylol:
Control of proteolytic enzymes.
FBA Pharmaceuticals Ltd.

Distributed by:
__
Boehringer ingelheim (Canada) Ltd.
2121 Trans Canada Highway, Dorval, P.Q. H9P 1J3
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C O N TR IBU AN TS

Toute communication initiale doit etre adressee au Coredacteurs, CP 8650, Ottawa, ON
K1G 0G8 sous la mention: “Le journal canadien de chirurgie”.
Manuscrits. Les texts originaux des articles
et des autres communications y compris un
nombre limite de rapports sur des cas speciaux doivent etre rediges en double exemplaire, en franpais ou anglais, et accompagnes
d’une lettre demandant leur publication dans
le Journal. Veuillez les dactylographier sur une
seule face d’une feuille normal avec double
interligne et grandes marges.
Illustrations. Les illustrations telles que des
photographies d’appareils cliniques, des radiographies, des photomicrographies, des graphiques et des digrammes doivent etre fournies sous la forme d’epreuves sur papier glace
sans montage, les bordures intactes, d’un format
ne depassant pas 12 x 17 cm. Chaque illustra
tion doit etre munie d’une legende dactylographiee sur une page separee du texte de
1article. S il s’agit d’une photomicrographie,
expliquez le contraste et l’echelle de l’agrandissement. Les lettres qui servent a identifier
les elements d’une illustration doivent etre d’u
ne dimension suffisante afin de demeurer visi
bles lorsque les necessites de l’impression imposent une reduction de l’image fournie. II
ne faut pas qu’on puisse identifier un patient
grace a une illustration a moins qu’il n’y ait
expressement consenti par ecrit; faute de per
mission les traits de sa physionomie doivent
etre obliteres. Les illustrations en couleur ne
seront publiees qu’aux frais de leur auteur.
Si 1illustration provient d’une autre source que
celle de 1 auteur, il convient d’obtenir tant de
Tauteur que de l’editeur de l’ouvrage dont elle
est tiree, 1 autorisation de s’en servir aux fins
de la publication.
Tables. Il faut en les etablissant se conformer
au format rectangulaire du Journal et les
rediger sur des feuilles separees du texte, une
table par feuille.
References. Celles-ci doivent etre citees dans
le texte au moyen d’un chiffre et groupees
dans 1 ordre a la fin de votre article en vous
conformant a la maniere de faire adoptee par
ce Journal. Les references a des periodiques
doivent etre conformes a celles qu’adopte
VIndex Medicus.
Un resume qui ne doit pas depasser 125 mots
doit accompagner chaque article sur une page
separee.
Une epreuve en placard sera adressee a l’auteur de 1article avant sa parution; on ne peut
autoriser que de legeres retouches. Ce n’est
qu au moment de restituer ces epreuves d’auteur au Journal qu’il y aura lieu de passer
commande de reimpression.
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ABSTRACTS OF PAPERS PRESENTED AT THE ANNUAL MEETING
OF THE CANADIAN ORTHOPAEDIC RESEARCH SOCIETY,
HELD IN OTTAWA, ONTARIO, MAY 25 AND 26, 1975
1. A ugmentation of Bone H ealing
Supplemental D irect -C urrent
E lectricity

by

D. A. MacKenzie and C. Knowles
Because the Harris fracture-healing model
produces nonunion it is ideal for quantitat
ing the ability of supplemental direct-current
(DC) electricity to augment the rate and ca
pacity of fracture healing.
In this preliminary study transverse single
saw cuts were created at the junction of
the proximal and middle thirds of the radius
in a control group of mature dogs. Although
these fractures were bilateral and unfixed,
the radii were reasonably stable and the
animals were able to walk on the 1st post
operative day. The reliability of the model
was confirmed by creating bilateral saw
cuts in six mature dogs. In all six dogs wellestablished, bilateral nonunion was demon
strated radiographically. Histologic exami
nation confirmed the presence of cartilage
in the gap.
The same procedure was performed in
a second group of four dogs, but in addition
they received 20 /xA of continuous DC cur
rent on one side, a dummy lead being
placed in the medullary canal on the other
(control) side. In three dogs, bone union was
demonstrated on non-screen radiographs and
was confirmed by histologic examination.
In a third group of 10 dogs, a pulsed DC
current unit was implanted. In the six dogs
sacrificed, there were definite signs of ad
vanced healing on the experimental side as
judged by non-screen radiographs and his
tologic examination.
Department of surgery,
Montreal Children’s Hospital,
Montreal, PQ.

2. A urosomes in R abbit A rticular
C artilage
A. F. Oryschak and F. N. Ghadially
Although gold salts are used in the treat
ment of rheumatoid arthritis, little is known
about the morphology and distribution of
gold in articular tissues. The aim of this

study was to find out whether gold injected
into the joint enters articular cartilage.
Sodium aurothiomalate (Myochrysine)
injected into the knee joints of rabbits pro
duced lysosomes (aurosomes) of a char
acteristic morphology in the chondrocytes of
articular cartilage. Such lysosomes are mor
phologically distinct from others and from
those present in joints injected with sodium
thiomalate. With the aid of electron-probe
x-ray analysis, gold and phosphorus were
demonstrated in the aurosomes.
Numerous coated vacuoles also developed
in the chondrocytes in joints injected with
sodium aurothiomalate. It is thought that
these vacuoles are involved in the transport
of a gold-protein complex and that the auro
somes evolved from the coalescence of such
vacuoles with primary lysosomes.
Department of pathology,
University Hospital,
Saskatoon, SK.

3. B iofeedback A pplied to P atients
with A bove-Knee A mputations
G. R. Fernie, J. P. Kostuik, C. McLaurin
and B. Zimnicki
In training a patient with an above-knee
amputation it is important to teach him to
ensure that the knee joint of the prosthetic
limb is fully extended before he places any
weight upon it. If not he will be unstable
and may fall. A simple device helps train
amputees in this aspect of walking. The de
vice consists of a buzzer that sounds when
the knee is flexed and is silent when the
knee is fully extended. It has been used
effectively for over a year at the amputee
centre of the Toronto Hospital. Biofeedback
techniques are being applied to correct other
common errors made by amputees. In addi
tion to aiding the physiotherapist in the
training sessions, these devices also permit
patients to use their time in hospital better
by enabling them to exercise in the absence
of the physiotherapist but still with a degree
of automatic supervision.
The experienced amputee might benefit
by the provision of continuous proportional
feedback of the angle of flexion of the knee
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joint, so a second device has been designed
to fulfil this need. This system uses tactile
stimulation of the skin of the stump.
Amputee Research Centre,
Toronto Hospital,
Weston, ON.

4. B lood Supply of the Cortex
G rowing and A dult B one

in

A. Trias

The role of the arterial and venous systems in
the bone cortex was examined in the femora
of dogs and rabbits. Study of the anatomy
revealed two distinct vascular networks. The
first, seen only in young growing bone, is a
functional network of vessels of capillary
calibre, which form rectangular meshes,
longitudinally oriented, and which do not
divide by dichotomy but anastomose with
each other with no change in calibre. This
system is continuous with the deep layer of
the periosteum and that of the endosteum
and permeates the whole cortex. As the
haversian systems are formed, a second,
new, system appears — the supply system.
It consists of arteries and veins radiating
from the bone marrow, penetrating the
cortex in a straight line and then branching
in arborescent fashion. The vessels anasto
mose freely with the mesenchymal system.
In the younger cortical bone, when the
functional system prevails, the flow appears
to be centripital. In adult bone the arterial
cortical flow via the supply system is cen
trifugal, but the blood returns centripitally
to the marrow before leaving the bone main
ly through metaphyseal veins. The changes
in cortical circulation from growing to adult
bone reflect its changing histologic struc
ture.
Department of orthopedics,
Centre Hospitalier Universitaire,
Universite de Sherbrooke,
Sherbrooke, PQ.

5. Collagen A rchitecture of N ormal
AND OSTEOARTHRITIC HUMAN ARTICULAR
Cartilage

R. U. Repo, K. Newland and L. Johnston
The architecture and the morphologic disin
tegration of collagen in osteoarthritic arti
cular cartilage was investigated by scanning

Vol. 19

electron microscopy in 14 tibial plateaus (7
were normal by the criteria of Collins).
The collagen was exposed by partial re
moval of proteoglycans with 4 M guanidinium hydrochloride and was dehydrated by
sublimation with camphene to minimize
artefactual distortion of the tissue.
The study of normal articular cartilage
showed that the tangential zone of collagen
is arranged generally along the split lines of
Hultkrantz, but below this the split lines
do not correspond to any recognizable col
lagen orientation.
Osteoarthritic specimens demonstrated
deep microfissures and were direct exten
sions of fibrillation defects seen macroscopically. Selected specimens of early os
teoarthritic tibial plateaus demonstrated
microscopic fissuring of the collagen frame
work in planes perpendicular to the split
lines of Hultkrantz, suggesting that these
fissures may represent fatigue failure of
collagen occurring near the free edge of
the meniscus and the weight-bearing por
tion of the plateau.
Department of surgery,
University of Western Ontario,
London, ON.

6. Collagen Polymorphism in Ossifying
Bony R udiments of the H uman F etus

D. J. Gates and W. M. Rigal
Different types of collagen exist in bone
and cartilage. The synthesis of bone (type
I) and cartilage (type II) collagens in cul
tured bony rudiments of the human fetus
was investigated as a preliminary study of
collagen polymorphism in pathologic bone
formation in man. Normal long-bone rudi
ments from 6- to 16-week-old fetuses were
cultured under lathyritic conditions, in vitro,
for 12 hours in the presence of 14C-lysine
and 3H-proline. The various developmental
regions were dissected from the explants
after freezing in liquid nitrogen, then sub
jected to a sequential extraction procedure
designed to facilitate solubilization and re
moval of the newly synthesized (lathyritic)
and pre-existing, unlabelled collagens. Ex
tracts containing labelled and unlabelled
collagens were combined after dialysis, and
collagen subunits were separated on carboxymethyl-cellulose cation exchange columns
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using a linear sodium chloride gradient.
Peaks of radioactivity were identified by
collagen subunit type, and relative con
centrations of bone
and car
tilage ([a 1(II)]3fl) collagens were calculated
for each region of the explants. Changes in
the molar ratio of a 1:a 2 in calcified and
noncalcified regions indicate that the appear
ance of type I collagen is a prerequisite to
calcification in the ossifying bony rudiments
of the human fetus.
Department of surgery,
University of Alberta,
Edmonton, AB.

7. Comparison of Joint -F orce Loading
Patterns for V arus, V algus and
F lexion D e f o r m it ie s

at the

Kn e e

/. 7. Harrington
A bioengineering analysis of force trans
mission at the knee was carried out by the
dynamic three-dimensional technique of
Morrison, and the results were compared
with those calculated from a static frontal
plane analysis. Varus, valgus and flexion
deformities were assessed.
Major differences occur for joint-force
magnitude and location of the centre of
joint pressure at the knee using the two
different methods of analysis. The discre
pancies are most apparent for flexion de
formities.
In valgus limbs, the centre of joint pres
sure may be located in the medial joint
compartment for an appreciable portion of
the stance phase of the gait cycle, and at
periods when joint-force loading is maximal.
These results suggest that the centre of
joint-force pressure cannot be predicted ac
curately by static analytical methods. The
rationale of performing high tibial osteo
tomies based on static frontal plane calcula
tions is questionable.
Since an osteotomy to provide ideal joint
loading throughout the stance phase of the
gait cycle cannot be designed, the most
practical method of osteotomy might be
simple, anatomical restoration of knee align
ment.
Department of surgery,
Toronto East General & Orthopaedic Hospital,
Toronto, ON.
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8. E f f e c t s o f E lec tr ic al S t im u l a t io n
on B o n e G rowth I n V itro a n d o n
F r ac tu re H ea lin g

W. G. de Haas* and J. Watson f
A noninvasive technique of electrical stimu
lation of bone growth and fracture healing
was studied in vitro and in a patient with
a fracture. The growth of embryo chick
tibias was found to accelerate in pulsed
magnetic and pulsed electric fields, and
healing in osteotomized radii in rabbits was
likewise accelerated, though inconsistently,
when radii were subjected to a pulsed mag
netic field. In the case of the patient, a 50year-old man with a post-traumatic pseudarthrosis of the tibia, treatment in a pulsed
magnetic field for 6 weeks resulted in bone
union 6 months later.
The principle use of a pulsating magnetic
field to induce an electric field at fracture
sites promises to have clinical application.
*Department of surgery,
University of Calgary,
Calgary, AB.
tDepartment of electrical engineering,
University College of Swansea,
Swansea, Wales.

9.

IMMUNOGENICITY OF OSTEOSARCOMA IN

the

R a t , I n d u c e d by M u r in e S a r c o m a
V irus -M o lo n ey

E. P. Urovitz, F. Longer, A . E. Gross,
A . A . Czitrom and S. K. Stylianos
The immunogenicity of a viral induced rat
osteosarcoma was studied by the lymphocyte
microcytotoxicity test. Intratibial injection of
murine sarcoma virus-Moloney (MSV-M)
resulted in the development of palpable
tumours at the injection site, which histopathologically appeared as osteosarcomas.
In 73% of animals these tumours pro
gressed and metastasized to lungs. Lympho
cytes from these “progressor” animals dem
onstrated an ability to kill osteosarcoma
cells in vitro (as quantitated in the micro
cytotoxicity test) while serum from these
animals abrogated or blocked the cellmediated cytotoxicity. In the remaining an
imals the tumours either failed to develop
or regressed spontaneously. Lymphocytes
from these “regressor” animals also dem
onstrated cytolytic activity against osteo-
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sarcoma cells in vitro, but serum failed to
block the lymphocyte-mediated cytolysis.
Both regressor and progressor groups dem
onstrated humoral cytotoxic antibodies to
tumour antigen on the basis of the ability
of their serum to kill tumour cells in vitro.
Department of surgery,
Mount Sinai Hospital and University of Toronto,
Toronto, ON.

Vol. 19

^Department of mechanical engineering,
McGill University,
Montreal, PQ.
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11. M ethod

of H emagglutination for
the S tudy of
Collagen-G lycosaminoglycan
Interactions

L. B. Conochie, J. E. Scott, W. P. Faulk
and A . Bailey

Y

<

The increased awareness by physicians of
loosening or breaking of the components of
total joint arthroplasty has emphasized the
need for experimental studies on the inter
face between the implants and host bone.
A suitable model was designed for labora
tory animals to serve as a vehicle for ex
amining this interface. The model consisted
of the replacement of a 1.9-cm segment of
the midshaft of the dog’s femur with a
metallic intramedullary device. The device
was cemented into place with polymethyl
methacrylate. After varying periods of full
weight-bearing, the bone and implant were
recovered and histologic thin sections ob
tained by a technique that preserved the
surgical polymer.
There were two impressive findings. First,
blood left on the endosteal surface of the
bone at the time of the operative procedure
weakened the bone-cement interface and
may have contributed to failure. Gaps of
500 to 1000 p,, filled with blood, were
seen, in contrast to very thin gaps where
the bone was prepared by scrupulous clean
ing before insertion of the polymer. Second,
cracks appeared in the surgical polymer, in
a radial fashion, running from the metallic
implant to the bone-cement interface. These
were often multiple, occasionally huge, and
probably were the product of “hoop stress”
— that is, tensile forces developing in the
cement as a result of shrinkage of the
methacrylate around an unyielding metallic
core. Calculations indicated that this hoop
stress can be large enough to exceed the
tensile strength of the polymer.

It has been postulated that the func
tion of various connective tissues in the body
is related to differences in their mole
cular composition and internal architecture.
The interaction of collagen and glycosaminoglycans in articular cartilage may be im
portant in determining its structure. Changes
in this interaction may have a bearing on
the susceptibility of articular cartilage to
undergo changes related to age and wearand-tear.
A simple method of hemagglutination,
originally designed to detect and measure
antibody can also monitor collagen-glycosaminoglycan and collagen-proteoglycan in
teraction in vitro under physiologic condi
tions of pH and ionic strength.
Tanned sheep erythrocytes coated with
soluble collagen are agglutinated in the
presence of certain connective-tissue poly
saccharides. The “strength” of the collagenglycosaminoglycan interaction is assessed by
serial dilution of the glycosaminoglycan so
lution until the end point of agglutination
is achieved.
In this system, chondroitin 4-sulfate and
dermatan sulfate interacted strongly with
collagen. Chondroitin 6-sulfate and heparan
sulfate interacted less strongly, and hyaluronate and keratan sulfate were extremely
weak interactors with collagen. This interac
tion requires that the triple helical native
collagen molecule be intact, since mild heat
denaturation of the collagen abolishes the
interaction. In control experiments, with
uncoated or albumin-coated erythrocytes,
there was no agglutination in the presence
of the connective tissue glycosaminoglycans.
This method of hemagglutination is rapid,
simple, economical and requires only small
quantities of purified material.

♦Department o f surgery,
Montreal General Hospital,
Montreal, PQ.

Department of surgery,
Montreal General Hospital,
Montreal, PQ.

10. Interface B etween B one and
P olymethylmethacrylate U nder
Load- bearing
/.

Miller,* D. Burke* and J. W. Stachiewiczf

\

4

*
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12. M icrocrystalline C ollagen : A n
E ffective H emostatic A gent to
R educe B one B leeding

E. L. Thrasher, W. H. Harris and
R. H. Cobden
An effective hemostatic agent that will re
duce bleeding from bony surfaces, yet not
inhibit osteogenesis is essential in orthopedic
surgery. Bone bleeding from osteotomy of
the greater trochanter, iliac-bone-graft donor
sites, intertrochanteric osteotomies or fracures, and many other skeletal injuries is an
important factor in operative and postopera
tive blood loss. Bone wax, oxidized cellulose
and thrombin gelatin foam are commonly
used despite the lack of quantitative data
confirming their value. Bone wax reduces
bone bleeding but interferes with osteo
genesis.
Microcrystalline collagen, a new agent
extracted from bovine hide corium and pre
pared as microcrystals (length, < 1 /T), main
tains the tertiary structure of the collagen
and thus binds platelets. Its efficacy as a
hemostatic agent applied to cancellous bone
was studied in a series of osteotomies of
the greater trochanter in 53 dogs. Micro
crystalline collagen reduced blood loss by
73% compared with control values and was
appreciably better than other test agents.
It reduced blood loss without interfering
with union of the greater trochanter after
repositioning.
In a series of patients undergoing total
hip replacement a similar study was carried
out. Various agents were applied to the
cancellous bleeding surface of the trochan
teric osteotomy. Microcrystalline collagen
reduced bleeding from the test site by 77%
and did so without interfering with union
of the greater trochanter.
Department of orthopedic surgery,
Massachusetts General Hospital,
Boston, MA.

13. N atural H istory
with an

of the P atient
I nfected T otal H ip
R eplacem ent

G. A. Hunter
Review of the natural history of 127 pa
tients with deep infection after total hip
replacement revealed that 19 died after the
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insertion or excision of the prosthesis. No
patient died who had a successful implant
in the appropriate position under a dry
wound.
Of the patients still living only 17 re
tained their hip implant in position without
further wound complications. The remain
ing patients had their hip implants excised;
most had dry wounds.
Poor management, despite early recogni
tion of the infection resulted in a high rate
of excision of the hip prosthesis.
The results of this survey indicate that a
second total hip prosthesis should not be
inserted following deep infection of the
first implant.
Important considerations are the dif
ficulties of distinguishing between a positive
wound culture and clinical infection of the
wound in arthroplasty of the hip, the bacteriologic aspects of deep infections with
reference to the use of prophylactic anti
biotics, and the dangers of metastatic in
fection in the postoperative period.
Division of surgery,
St. Michael’s Hospital,
Toronto, ON.

14. P attern

of Cortical B one Loss in
E x perim ental D isuse O steoporosis

H. K. Uhthoff, C. Palmer and Z. F. Jaworski
The effect of disuse on the humerus, radius,
ulna and third metacarpal was studied in
eight adult dogs over a period of 2 to 24
weeks. The dogs were immobilized in a
shoulder spica; no surgical trauma was in
troduced.
Radiologic and histologic measurements
suggest that bone is not lost gradually, but
in a phasic pattern. Early negative bone
balance was followed by positive balance at
12 weeks, which in turn was followed by
a second, more-pronounced, negative bal
ance. Measurement of the contribution
of the periosteal, endosteal and haversian envelopes to bone loss demon
strated an impressive periosteal bone loss.
At 24 weeks all cortices had regained a
normal density. Any study on the prevention
or treatment of disuse osteoporosis should
consider the phasic behaviour of bone loss
and the contribution of the three envelopes
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to it, as well as the individual behaviour of
each bone.

and form suggesting immune complex forma
tion. The work was extended as a prospective
study in which randomly selected arthritic
Department of surgery,
Ottawa General Hospital,
patients, all of whom were candidates for re
Ottawa, ON.
constructive surgery, were included. In addi
15. P ermanent D eformation of B one : tion to cartilage and synovial tissue biopsies,
the disease state and severity were assessed,
A n E xperimental Model in the Dog
and immunologic parameters in serum and
C. F. Moseley, V. H. Frankel,
synovial fluid were measured. Data on 208
A . H. Burstein and K. G. Heiple
patients studied for evidence of immune com
plex
deposition in cartilage have been cor
Study of two cases of traumatic bending of
related
with their diagnostic groups. In pa
long bones without evidence of fracture has
tients
with
classical RA, more than 92%
demonstrated, at follow-up, new bone forma
tion particularly on the concave aspect; in had positive findings. Of those with non
one case an onion-skin appearance was inflammatory arthritis, findings were posi
tive in 52% of patients with primary dege
noted.
nerative
arthritis and 20% of patients with
An animal model was developed to study,
secondary
degenerative arthritis. Findings in
in vivo, the nature of, and the response of
nonarthritic joint biopsies were positive in
bone to, plastic deformation.
An instrument applying a four-point 5% . The relatively high incidence of posi
bending load to the canine fibula during a tive findings in the primary degenerative
sterile procedure was designed so that the group suggests a potential relation between
load-deformation curve could be monitored some of these cases and RA, and the po
during application of the load. One fibula tential for immune mechanisms to be in
was subjected to loading into the plastic volved in pathogenesis. The proportion of
region. This was demonstrated by the shape positive findings in patients with classical RA
of the load-deformation curve and by the is highly significant when compared with
visual, palpable, and radiologic evidence of the proportion in any other group studied
residual deformation. With that load-de (P <0.001). These data support the notion
formation curve as a reference the other that cartilage-localized immune complexes
fibula was loaded within the elastic region in RA play an integral role in chronicity,
perhaps as a source of persisting antigen.
only as a control.
Histologic examination and examination
by ultraviolet light for tetracycline fluores
cence have failed to demonstrate either the
morphologic basis of plastic deformation or
a relation between the remodelling pattern
and the loading configuration.
Department of biomechanics,
Bingham Building,
Case Western Reserve University,
Cleveland, OH.

16.
P rospective B iopsy Study of
Collagenous T issues in A rthritic
P atients for E vidence of I mmune
Complex D eposition
E. Bennett, S. Richer and D. Cooke
Immunoglobulins (IgG, IgA, IgM) and com
plement components (B1C were previously
identified in the surface layers of articular
collagenous tissue biopsies of many patients
with rheumatoid arthritis (RA), in a location

Department of surgery,
Queen’s University,
Kingston, ON.

17. R esurfacing the A rticular
Cartilage of A dult R abbits by
M ultiple P erforations T hrough
Subchondral B one
N. Mitchell and N. Shepard
Articular cartilage was removed from both
distal femora of adult rabbits. One knee
served as a control; the other was studied
after multiple perforations had been made
through the subchondral bone. Animals
were sacrificed at intervals up to 1 year and
cartilage regeneration was studied by light
and electron microscopy. Initially a car
tilaginous material, staining heavily with
safranin 0, filled the holes, and under light
and electron microscopy this material re
sembled hyaline cartilage. By 12 months
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resurfacing of the cartilage had occurred,
though the material lost its hyaline appear
ance after 8 months and resembled dense
collagenous tissue. Since this tissue with
stood wear for 1 year it is speculated that
it may have some use in temporary resur
facing of partial cartilage defects.
Orthopaedic research laboratories,
Royal Victoria Hospital,
Montreal, PQ.
18. T he R eversibility of T issue
D ifferen tia tio n A round Screws

H. K. Uhthoff and J. P. Germain
Previous studies have demonstrated the in
fluence of mechanical factors on cell dif
ferentiation — movement around screws
inserted into compact bones led to bone
resorption and absence of movement led
to bone formation. The present study of 12
adult dogs showed that the morphology and
function of tissues were also subject to
mechanical factors. A 4-week-old callus,
formed under conditions of mechanical neu
trality, was resorbed when subjected to
gross movement. On the other hand bone
resorption resulting from movement around
the screw ceased and bone formation started
when the movement was suppressed. The
results, obtained over an 8-week interval,
were based on radiologic, histologic and
fluorescence microscopic examinations. It is
concluded that not only the differentiation
of undifferentiated cells but also the state
of differentiated tissues are influenced by
local mechanical factors.
Department of surgery,
Ottawa General Hospital,
Ottawa, ON.

19. Scanning E lectron M icroscopy

of

Superficial D efects in A rticular
C artilage

F. N. Ghadially and A. F. Oryschak
Superficial defects approximately 2 mm in
diameter were produced by removing a thin
shaving of cartilage from the medial femoral
condyle of the rabbit. On the surface of
these defects many chondrocytes and their
lacunae, laid bare by this procedure, were
seen. In specimens collected over the 4- to
14-day period after operation, the lacunae
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became progressivly shallower and their
margins rounded and obscured. At 3 to 4
weeks a few, small, thread-like and ribbon
like structures were seen arising from the
margins and surface of the defects. With the
passage of time these became quite promi
nent, and at 6 months numerous wave-like,
band-like, rope-like and thread-like forma
tions were seen coursing over the floor of
the defects.
Collectively these formations may be re
ferred to as “flow formations” for they ap
pear to derive from streaming or flowing
of cartilage substance, engendered by the
pressure of load-bearing and shearing
forces in the joint. The importance and
ultimate fate of these new structures, re
vealed by scanning electron microscopy, re
main to be determined.
Department of pathology,
University Hospital,
Saskatoon, SK.

20.
Stress A nalysis of the
Subtrochanteric R egion of the F em u r
G. V. B. Cochran, J. Fielding and
R. E. Zickel
The subtrochanteric fracture is a clinical
problem in biomechanics; the relative fre
quency of nonunion or failure of fixation,
or both, is related to high mechanical stress.
Experiments were designed to determine
subtrochanteric stresses in relation to load
ing, muscle forces and devices for fracture
fixation.
The subtrochanteric segment of six intact
human femora was instrumented in vitro,
with electrical resistance strain gauges. Sta
tic loads were applied in three configura
tions: directly to the femoral head, simulat
ing two-leg stance; indirectly by apparatus,
simulating single-leg stance with active ab
ductors; and indirectly, simulating single-leg
stance with active abductors and tensor
fascia lata. Strain measurements during load
ing were obtained and data converted to
stress.
For two-leg stance, experimental results
supported the theoretical stress calculations
of Koch and of Rybicki and colleagues.
For single-leg stance, results indicated that
abductors alone greatly increase subtrochan
teric strain, up to 600% over two-leg stance.
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Counteracting forces, represented by the in immature animals worsened with con
tensor fascia lata, exert a protective effect, tinued dislocation reaching a maximum with
limiting stress to acceptable levels. After in 24 hours. Recovery did not start unti'
osteotomies, performed to simulate frac 7 days after dislocation.
^
tures, stresses in the fragments varied with
The perfusion deficit was most severe intype of internal fixation, muscle action and immature animals and was maximal in the
loading configuration. The addition of plate anteromedial portion of the femoral head,
fixation to intact specimens, representing which was either devoid of perfusion or con
healed fractures, produced substantial “stress siderably underperfused within 10 minutes
protection”; bone stress was reduced 30 to of dislocation. Recovery of perfusion within
50% near the plate, and medial-lateral dis the femoral head of immature animals coin
tribution was altered markedly. In contrast, cided with the development of an extraos
a “Zickel” nail intramedullary device, pro seous network of epiphyseal blood supply
vided secure fixation while maintaining more and drainage on the posteroinferior femoral
physiologic stresses in bone with lower stress neck.
in the metal.
Reduction of the dislocated hip in grow
Alteration in stress patterns caused by ing animals damaged the blood supply to
internal fixation may be important in frac the femoral head, but early reduction en
ture healing in view of the recognized rela hanced complete recovery of blood supply.
tion of mechanical stress to the deposition Reduction 12 hours or longer after the dis
and remodelling of bone. Regarding strength location did not benefit the rate and extent
of internal fixation, the “device-bone unit”, of return of perfusion in the femoral head.
rather than the strength of the device alone,
In adult animals, the intraosseous epiis an essential concept.
physeometaphyseal anastomoses across the
obliterated growth plate minimized the ef
Department of orthopedic surgery,
St. Luke’s Hospital Centre,
fects
of damage to the extraosseous epi
New York, N Y.
physeal nutrient system.
Aseptic necrosis of the femoral head,
21. T raumatic D islocation of the H i p :
demonstrated histologically, occurred in
A M icroangiographic, H istologic and
most animals regardless of skeletal maturity
Radiologic Study
or reduction of the hip dislocation. It was
Clive P. Dincan and Sun-Shik Shim
more common and extensive in immature
animals.
Experimental study of traumatic posterior
Abnormal radiologic features within the
dislocation of the hip in 210 rabbits (60
femoral head were seen infrequently be
mature, 150 immature) revealed that the
tween 5 and 10 weeks after dislocation,
dislocation caused circulatory embarrass
despite the high incidence of aseptic necrosis,
ment to the femoral head in both adult and
but correlated well with the histologic find
immature rabbits. The major causative fac ings.
tor was damage to the extraosseous epiphyseometaphyseal vessels of blood supply Department of surgery,
of British Columbia,
and drainage. Disturbance of the circulation University
Vancouver, BC.
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DEXON VERSUS CONVENTIONAL SUTURES IN HERNIA REPAIR*
N. BALTAZAR, MDt and D. W. B. JOHNSTON, MD, FRCS[C], FACSt
»n unselected study of 87 inguinal hernior'•hapies was carried out over a 2-year period
ising polyglycolic acid (Dexon) sutures in 46
procedures and conventional sutures in the re
naming 41. Tissue reaction was the same with
ooth types of suture; however, the incidence of
recurrence was lower with the use of con
ventional sutures. This study has not confirmed
the superiority of Dexon sutures reported in
other studies.
Une etude portant sur 87 cas non selectionnes
d’herniorrhaphies inguinales a ete realisee sur
une periode de 2 ans, alors que des sutures
d’acide polyglycolique (Dexon) ont ete utilisees
dans 46 interventions et des sutures conventionnelles dans les 41 autres operations. La
reaction tissulaire a ete identique avec les deux
types de sutures; toutefois, la frequence des
recidives a ete plus faible avec I’emploi des
sutures conventionnelles. Cette etude n'a pu
confirmer la superiorite des sutures Dexon signalee dans d'autres etudes.

P olyglycolic acid (Dexon) suture is a re
latively new absorbable nonprotein material.
Reports are unanimous in asserting that
polyglycolic acid is absorbable, has superior
tensile strength to conventional suture ma
terial and causes minimal tissue reaction.1' 8
Postlethwait1' 2 reported that one third of
the initial strength of polyglycolic acid is
lost in 7 days and about 80% by 2 weeks.
Lichtenstein'-1 stated that any suture material
that loses most of its strength within 2
weeks should never be used to close sup
portive structures (aponeurotic tissues of
the abdominal wall). Rabbits regain less
than 30% of the original tensile strength at
the wound site within 2 weeks, and after 2
months the wound is only about 41% as
strong as normal tissue,9 Postlethwait2 con
cluded that longer retention of strength by
*From the department of surgery, Westminster
Hospital and University of Western Ontario, Lon
don, ON.
tFormer resident in surgery, Westminster Hos
pital.
tChief of service — surgery, Westminster Hos
pital and clinical professor in surgery, University
of Western Ontario.
Reprint requests to: Dr. D. W. B. Johnston, Chief
of service — surgery, Westminster Hospital, PO
Box 5701, London, ON N6A 4S2.

the polyglycolic acid suture would be de
sirable.
We compared Dexon with conventional
suture material used for repair of 87 in
guinal hernias in 76 patients.
M ethods

Numbered envelopes prepared in advance
were opened by the supervising nurse in
the operating room. Numbers were chosen
from a random table and the surgeons used
the suture material designated. Sutures de
signated as conventional were Dacron, cot
ton or silk. Cotton alone was used for all
layers in a few cases. Conventional sutures
were used in 41 repairs. Dexon suture was
used for all layers in 46. In several patients
undergoing bilateral repair, polyglycolic acid
sutures were used on one side and conven
tional sutures were used on the other.
R e su l t s and D iscussion

Surgeons who were unaware of the su
ture material used evaluated the wound
sites at the follow-up examinations. Factors
adversely affecting wound healing, such as
obesity, systemic disease and age were not
taken into consideration in patient selection.
Patients were followed up and examined
after a period ranging from 9 to 37 months
postoperatively. Criteria used in these ex
aminations were: (a) recurrence, (b) early
and late complications, and (c) hypertrophy
of scar tissue.
In all, 80 operative repairs in 69 patients
were evaluated (follow-up rate, 91% ). Of
these, 41 were repairs with Dexon and 39
with conventional sutures. Six recurrences
were observed in the Dexon group (14.6% )
and three in the conventional group (7.7% ),
indicating no superiority of Dexon su
ture in the repair of inguinal hernias. In
fact, there is a low probability that the use
of nonabsorbable material is more suitable
in preventing recurrence (x.2 = 0.4, 1 df).
The postoperative complication rate in
our study was similar in the two groups
(Table I). With respect to scar tissue forma
tion, two operative scars in each group were
more prominent than the rest.
Gallitano and Kondi5 reported that the
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TABLE I —P ostoperative C omplication R ate
Complications

Who
brought
the
Muller
Total Hip
Joint
Prosthesis
to
Canada?

Dexon
suture

Conventional
sutures

1

1

4

1

Slight induration and
tenderness..................
Slight edema and
ecchymosis.................
Hematoma (no drainage
required). . . ..............
Small subcutaneous
abscess (drained). . . .

0

2

0

1

T o tal.......................

5

5

rate of incisional hernias with Dexon (used
in fascial layers) was markedly diminished
in closures of abdominal incisions. In our
cases we found a 7% difference in the rate
of recurrence in inguinal hernia repairs.
C o n c l u s io n s

In spite of the impressive results from
other reports indicating less tissue reaction
from polyglycolic acid suture than from
other suture materials, our study showed no
substantial difference. We are not convinced
of the advantages of polyglycolic acid su
ture for closure of supportive structures and
therefore we routinely use Ethiflex suture
(synthetic Teflon-Dacron) for closure of
the fascial layers in the repair of inguinal
hernias.
We acknowledge the help of professor Charles
Rand, Department of epidemiology, faculty of
medicine, University of Western Ontario.
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U S E O F T H E R M O G R A P H Y F O R T H E E A R L Y D IA G N O S IS O F D E E P V E IN
T H R O M B O S IS F O L L O W IN G H IP O P E R A T IO N S *

AT T KALAMCHI, MB, ChB, FRCS[C]t and LEO J. MAHONEY, BA, MD, MS, FRCS[C]t
Up to 50% of patients suffer from deep vein
thrombosis (DVT) after major hip surgery.
Frequently DVT cannot be diagnosed clinically.
To the present, venography alone has been used
in these patients, but it is tim e consuming,
necessitates an intravenous dye injection and
is not without complications. Now, however,
the technique of thermography is available as
an additional diagnostic aid.
The results of thermography were assessed
in 24 patients who had recently undergone
major hip operations and compared with those
obtained by venography. Thermography did
identify DVT in the lower leg veins of patients
with no clinical symptoms, but higher obstruc
tions were only diagnosed by venography.
Thermography gave one false-positive result
later disproven by venography.
Thermography has the advantage of being
noninvasive and economical; it will become more
useful when smaller portable systems are
developed.
Jusqu'a 50% des patients qui subissent une chirurgie majeure de la hanche, ont a souffrir de
thrombose veineuse profonde (TVP). Frequemment, la TVP ne peut etre diagnostiquee cliniquement. Jusqu'a present, seule la phlebographie a ete utilisee chez ces patients, mais elle
est fastidieuse, requiere I'injection intraveineuse
d'un colorant et n'est pas sans complication.
Toutefois, on peut maintenant avoir recours a la
thermographie comme technique de diagnostic
additionnelle.
Les resultats thermographiques ont ete evalues chez 24 patients qui avaient subi depuis
peu une intervention chirurgicale majeure de la
hanche, et ils ont ete compares a ceux obtenus
par phlebographie. La thermographie a pu iden
tifier les TVP dans les veines inferieures de la
jambe chez des patients exempts de symptomes
cliniques, mais les obstructions superieures n'ont
pu etre diagnostiquees que par phlebographie.

*From the departments of orthopedic and general
surgery, St. Michael’s Hospital, University of
Toronto, Toronto, ON.
tSenior resident in
Michael’s Hospital.

orthopedic

surgery,

St.

tSenior surgeon, St. Michael’s Hospital, and
director, thermographic diagnostic services, St.
Michael’s Hospital. Assistant professor of sur
gery, University of Toronto.
Reprint requests to: Dr. L. J. Mahoney, 55
Queen St. E, Ste. 403, Toronto, ON M5E 1R5.

La thermographie a donne un faux resultat positif qui a pu, plus tard, e tre rejete par phlebo
graphie.

La thermographie a I'avantage d’etre une tech
nique non-envahissante et economique; elle deviendra plus utile lorsque d es system es portatifs, moins encombrants auront ete mis au point.

T he proportion of patients in whom deep
venous thrombosis (DVT) developed after
hip surgery has been reported to be as high
as 50% .11 2 Clinical signs may be mislead
ing or totally absent in many patients.
Lambie and colleagues,3 who reported on
111 surgical patients considered to be at
high risk, found that this complication
developed in almost half the patients and
of them, the diagnosis was unsuspected
clinically in two thirds despite careful scru
tiny; of those in whom the diagnosis was
made clinically, the diagnosis was falsely
positive in a quarter. Orthopedic surgeons
are unsure of the value of prophylactic anti
coagulants in patients with proven DVT4' 8
and there is no proof that such treatment
actually decreases the incidence of fatal
pulmonary embolism; neither is there gen
eral agreement on the anticoagulant drug of
choice nor the ideal method of administra
tion.9'13
Because clinical diagnosis is fraught with
error, there is need for a simple, nonin
vasive, rapid, readily repeatable, diagnostic
test to identify DVT in the lower limb for all
susceptible patients with or without demon
strable clinical signs. Cooke and Pilcher14
considered the chemical activity in the limb
accompanying, and consequent upon, a
thrombotic episode. They suspected that
increased heat, though subclinical, could
be present from an early stage and subse
quently reported the successful use of ther
mography to detect subclinical increases of
limb heat in patients with DVT. This work
and that of Pilcher2 stimulated our study.

M ethods

and

Patients

Principles of Thermography
Under standard conditions, the thermal
contours or patterns that exist on exposed
human skin are determined by applying the
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principle that heat is conducted to the skin
secondary to variations in blood flow.
The infrared radiation emitted by the
skin can be collected optically, transformed
into electrical impulses, amplified and pre
sented in display form. This is the essence
of the AGA thermovision system 680 (Agatronics Ltd., Toronto, Ont.) that we have
used. It has been described in detail by
Clark.15 The immense advantage of a tech
nique as noninvasive as routine photography
is obvious.
Technique o f Screening

Each patient is taken by stretcher to a
room where the constant ambient tempera
ture is maintained between 20 and 22°C. The
patient is exposed (except for a T-binder)
below the umbilicus for 20 minutes before
examination. The legs at the ankles are sup
ported on a bolster under the Achilles
tendon, which separates the ankles by 15
cm and keeps the calves clear of the stretcher
by 5 cm. Twenty minutes is ample time for
the surface temperature of the leg to
equilibrate with the ambient temperature.
The time taken to examine one patient
averages 20 minutes (after 20 minutes of
TABLE I.—Summary
Patient

of

R esults

of

Age, sex Diagnosis

1.......................
2 ......................
3 ......................
4 ......................
5 ......................
6 ......................
7 ......................
8 .....................
9 ....................
10....................
11....................
12....................
13....................

57
66
67
69
85
60
61
70
70
78
77
49
71

14....................

72

15......................
16......................
17......................
18.....................
19......................
2 0 ......................
2 1 ....................
2 2 ......................
2 3 ......................
2 4 ....................

69
67
77
56
75
68
76
65
62
53

M F L hip
M OA L hip
F OA R hip
M OA R hip
F F R hip
M Moore’s P
F OA R hip
F Failed TH
F OA R hip
F F L hip
F
F R hip
F
F L hip
M Nonunion,
F R hip
F Nonunion,
F R hip
F AN L hip
F F L hip
F F L hip
M F L hip
F OA L hip
F F L hip
F F R hip
F OA R hip
M F R hip
M OA R hip

Vol. 19

cooling). As recommended by Cooke and
Pilcher,14 the thighs and calves are exam
ined separately. The thermographic patterns
are recorded in shades of grey (white =
warm; black = cool) and coloured iso
therms on Polaroid film. All thermographic
examinations have been performed and in
terpreted by one of us (LJM).
In addition to thermography, venography
was performed in patients whose first ther
mogram after hip surgery was performed
between the 2nd and 4th postoperative day
and then every 3 or 4 days throughout the
postoperative period. In such patients one
satisfactory venogram is obtained after the
first thermogram, usually between the 3rd
and 5th postoperative day. Each patient
is then observed until fully ambulatory
or until the time of discharge from the
orthopedic unit. The presence or absence of
clinical signs of DVT were recorded in all
patients by one of us (AK).
Patients

In the 12-month period ending July 1974
we were able to complete this protocol for
24 patients. The details concerning sex, age
and surgical procedure are summarized in

T hermography
Procedure
IF
TH
TH
TH
IF
Revised to TH
TH
Revision of TH
TH
IF
IF
IF
TO& BG
Moore’s A
TH
IF
Thompson P
IF
TH
IF
IF
TH
IF
VO

and

Venogrpahy

Clinical
signs of D V T
—
—

—

in

24 P atients*

Thermogram Venogram
—
—
—
—
—
—

—

—

—

—

—
—
—
—

+

—
—
—
+
+
+
+
+

—
—
—
—
+
+
+
+
+

+

+

+

+

+
+
+
+

+
+
+
+
+
+
+
+

+

—

+
—

—
—

—

—

—

—

+
+

—

—

—

F = fracture, L = left, R = right, OA = osteoarthritis, P = prosthesis, TH = total hip replace
ment, IF = internal fixation, AN = aseptic necrosis, TO = trochanteric osteotomy, BG = bone graft,
A = arthroplasty, VO = varus osteotomy.
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Table I; this table also indicates the clinical,
thermographic and venographic findings in
all the patients.
R esults

Fig. 1.—Positive thermogram — marked in
crease in heat in whole limb (white = warm).

Fig. 2. —Positive venogram indicating extensive
clot in soleal vein.

Eight patients (1 to 8) showed no evid
ence of DVT on clinical, thermographic or
venographic examination.
Ten patients (9 to 18) showed evidence
of DVT on thermographic (Fig. 1) and
venographic (Fig. 2) examination. Five of
these (nos. 11, 13, 14, 16 and 18) had
clinical evidence of DVT at the time of
the first thermographic examination. In two
(10 and 15) the clinical evidence was
equivocal. Three patients (9, 12 and 17)
had no clinical suggestion of DVT through
out the postoperative period. In patient no.
16, a 67-year-old woman with an inter
trochanteric fracture of the left hip, internal
fixation with Richards screw and plate was
done 24 hours after injury. The patient
developed clinical signs of DVT in the left
leg on the 3rd postoperative day. Thermo
gram on the 3rd postoperative day was posi
tive (Fig. 1). Venogram on the 4th post
operative day was also positive (Fig. 2).
Two patients showed evidence of DVT
on venography, but serial thermograms were
normal. In one (no. 20) the clinical evid
ence was equivocal. One patient (no. 19)
had no clinical suggestion of DVT.
In two patients (21 and 22) localized
high femoral thrombosis in the abnormal
leg was demonstrated by venography. We
could not prove by means of thermography,
the presence of high femoral throm
bosis on the operative side. The increased
heat in the upper thigh due to the operation
obscured the thermogram immediately and
this heat increase persisted throughout the
period of observation. There was no clinical
suggestion of DVT in either patient. In
patient no. 21, a 76-year-old woman with an
intertrochanteric fracture of the right hip,
internal fixation with Richards screw and
plate was carried out within 24 hours of the
accident. There were no clinical signs of
DVT throughout the postoperative period.
Thermography was normal on the 5th, 8th
and 12th postoperative days (Fig. 3). Veno
gram on the 6th postoperative day was
positive (Fig. 4).
Two patients had normal venograms, but
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definitely positive thermograms. One (no.
24) had extensive ecchymosis and swelling
of the lower leg following a femoral osteo
tomy; clinically it was obvious that the
thermogram would be of no diagnostic
value. In the other patient (no. 23) there
was no clinical suggestion of DVT. How
ever, we were unable to find a cause for
this false-positive thermogram.
Among 10 patients with normal veno
grams there was one false-positive thermo
gram and among 5 patients with venographic
evidence of DVT in the calf there were two
false-negative thermograms.
D iscussion

Fig. 3.—Thermogram demonstrates increased
heat in upper thigh around operative site — a
constant thermographic finding in postoperative
hip surgery.

Fig. 4. —Positive venogram indicating presence
of clot high in femoral vein. There was no clot
in distal venous system.

In the early diagnosis of DVT of the
lower limb, venography is the only method
of examination that has an accuracy ap
proaching 100%. It is time consuming,
necessitates an intravenous injection of dye
and is not without complications. Because
it is noninvasive and because the cost of
each test is reduced by two thirds, thermo
graphy has obvious advantages over veno
graphy.
We did not find thermography as ac
curate as did Cooke and Pilcher.14 How
ever, as a screening tool for the examina
tion of patients with no clinical suggestion
of DVT, it is useful in the identification of
thrombosis of the soleal and popliteal
veins. Because of the heat generated by the
postoperative reaction after hip operations,
thermography is of no value in identifying
patients with localized high femoral throm
bosis on the side that has been operated on.
Although none of our patients had veno
graphic evidence of iliofemoral thrombosis
on either side, the presence of postoperative
reaction following hip operations would
make such a diagnosis difficult, thermographically, but would not be a problem in pa
tients on medical services who had not had
a recent surgical procedure involving the
hip or leg. The definitive diagnosis of DVT
in patients with positive thermograms, as
well as those with suggestive clinical find
ings, still must depend on venography.
Although the thermovision system is
mobile, it is unwieldy. In a hospital where
patients are accommodated two to a room,
the logistics of wheeling the apparatus from
one room to another are practically impos-
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sible. The suitability of a battery-operated,
completely portable, small unit for this pur
pose (AGA thermovision 750) is being in
vestigated.

5. Evarts CM, Feil El: Prevention of throm
boembolic disease after elective surgery of
the hip. J Bone Joint Surg [Am] 53: 1271,
1971
6. Sevitt S, G allagher NG: Prevention of

venous thrombosis and pulmonary embolism
in injured patients. Trial of anticoagulant
prophylaxis with phenindione in middle-aged
and elderly patients with fractures of neck
of femur. Lancet 2: 981, 1959

C onclusion

Following hip operations, thermography
of the lower limb is a useful screening tech
nique in diagnosing deep venous throm
bosis of the soleal and popliteal veins. It is
economical and noninvasive. The thermo
vision system used for this study is mobile,
but unwieldy. It is hoped that a completely
portable, small unit will soon become avail
able.
We are indebted to the department of visual
education, St. Michael’s Hospital, Toronto, for
their unstinting and cheerful aid in the prepara
tion of the prints, and to Miss K. Arthurs for
her patience and help in the preparation of the
manuscript.

7. Sevitt S: Venous thrombosis and pulmonary
embolism. Their prevention by oral anti
coagulants. Am J Med 33: 703, 1962
8. Simon TL, Stengle JM: Antithrombotic
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PROPHYLACTIC ANTIBIOTIC THERAPY AND HEART VALVE
REPLACEMENT*
T. W. AUSTIN, MD, FRCP[C], J. C. COLES, MD, FRCS[C], FACS, R. FINLEY, MD
and B. SCHIEVEN, BA, RT

Patients undergoing cardiac bypass for heart
valve replacement maintained adequate blood
concentrations of cloxacillin throughout the dura
tion of bypass, provided their initial blood con
centration was in the therapeutic range. Blood
levels related to the time between the last pre
operative dose of antibiotic and operation. Maxi
mal values were achieved if an intraoperative
bolus of drug was given.

agent used, cardiac bypass was asso
ciated with a precipitous drop in blood
antibiotic concentrations to subinhibitory
values.3 A second study suggested that pro
vided prepump values were satisfactory such
a phenomenon did not occur.4 Our study
attempts to clarify this controversy.

Des patients qui ont subi une derivation cardiaque pour le remplacement d’une valvule
cardiaque ont maintenu des concentrations adequates de cloxacilline pendant tout le temps ou
ils ont ete sous derivation, en autant que ies
concentrations initiales etaient a I'interieur des
taux therapeutiques. Les taux sanguins etaient
relies a I’intervale de temps ecoule entre la
derniere dose d’antibiotique administree avant
I'operation et (’intervention elle-meme. Les valeurs maximales ont ete obtenues lorsqu'une
dose massive de medicament a ete donnee pen
dant I'intervention.

Twelve adult patients (seven women, five
men) undergoing single valve replacement
(nine aortic, three mitral) in late 1974 and
early 1975 were studied. The average age
was 58 years (range, 16 to 76 yr). In all
cases the preoperative serum creatinine
concentration was less than 1.5 m g/dl and
there was no evidence of hepatic dysfunc
tion as judged by normal values for serum
bilirubin, alkaline phosphatase, lactic dehy
drogenase and serum glutamic oxaloacetic
transaminase concentrations.
Ten patients received ampicillin plus
cloxacillin, while two, with a history of an
allergy to penicillin, received lincomycin.
The dose of each antibiotic in all cases was
0.5 g every 6 hours. The medication was
given orally 1 day before operation and
by intramuscular injection on the day of
operation. In the later part of the study,
additional antibiotic was given in standard
dosage intraoperatively by intravenous bolus
injection.
The time of the last dose of antibiotic
prior to the initiation of cardiac bypass, to
the nearest half-hour, was recorded, as were
the times at which intraoperative blood
samples were obtained. These were taken
on three occasions: just before initiation of
bypass; 30 minutes later, while on bypass;
and immediately on completion of bypass.
All blood samples were taken from the fe
moral artery line, allowed to clot and then
spun down. The resultant serum samples
were stored at —70°C until assayed.
The volume of blood used in priming the
pump oxygenator, as well as of any blood
given intraoperatively, was recorded, as
were those of other solutions given during
the operative period.

of the associated mortality,1 in
fection of valve prostheses remains of major
concern to the cardiovascular surgeon. Cur
rently, patients undergoing heart valve re
placement receive prophylactic antibiotic
therapy in the intraoperative and early post
operative period. Although the benefits of
such a practice are questionable, the cur
rent low rate of early postoperative valvu
litis- makes it unlikely that a definitive
study of risks v. benefits would, or could, be
undertaken.
Current concern, we believe, should be
directed to the appropriateness of antibiotic
used, judged by the data available on or
ganisms causing prosthetic valvulitis and
their corresponding antimicrobial sensitivity.
Further, the optimal timing and duration
of such therapy as well as the optimal drug
dosage warrant consideration. The latter is
of importance since data .are conflicting.
One study indicated that despite the

B ec a u se

*From the departments of surgery and medicine,
Victoria Hospital, London, ON.
Reprint requests to: Dr. T. W. Austin, Infectious
disease consultant, Victoria Hospital, 391 South
St., London, ON N 6A 4G5.
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Serum cloxacillin levels were determined
and the minimum inhibitory concentration
(MIC) and minimum bacteriocidal con
centration (MBC) estimated. The MIC and
MBC were ascertained with the aid of a
nonpenicillinase-producing strain of Staphy
lococcus aureus (ATCC 25923). The pa
tient’s serum was serially diluted with anti
biotic medium no. 3 (Difco Laboratories,
Detroit, MI). An 18-hour culture of
S. aureus, grown in beef-heart infusion broth
(Difco Laboratories), was diluted 1:100
and 1 drop of this, containing approximately
2.5 x 105 colony-forming units (CFU),
added to each dilution. Following overnight
incubation at 37°C the specimens were in
spected for turbidity, the MIC of greatest
dilution showing none. All dilutions were
subcultured on blood agar at 37°C over
night, the MBC being the greatest dilution
demonstrating no growth on subculture.
To determine serum cloxacillin concentra
tions a penicillin-resistant S. aureus (hos
pital strain) was used. It was prepared in a
fashion similar to the above but diluted to
approximately 6.0 x 106 CFU. Of this, 1.5
ml was added to 150 ml of antibiotic me
dium no. 11 (Difco Laboratories) in agar,
the mixture poured into a glass-bottom tray
(250 mm2) and allowed to cool. Cloxacillin
standards of known concentration (20.0,
10.0, 5.0, 2.5, 1.25 yug/ml) were prepared in
pooled human serum. The known standards
and unknown patient samples were allowed
to saturate 6-mm filter paper discs and these
discs were then firmly pressed onto the test
plate. The standards were tested in quadru
plicate and the unknowns in duplicate. In
all cases the discs were randomly applied.
After overnight incubation the zone of bac
terial inhibition around each disc was meas
ured with Vernier calipers to the nearest
0.5 mm and the average obtained for each
sample essayed. The standards were then
plotted on semilogarithmic paper and the
unknowns extrapolated from the resultant
graph.
Initially, patients received 250 to 500 ml
of blood in the form of a pump prime with
the occasional patient receiving an addi
tional unit of whole blood intraoperatively.
In the latter part of the study, patients often
received no blood. An additional 2 to 3 l
of electrolyte solution and dextrose were
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given intraoperatively. The average dura
tion of cardiac bypass was 114 minutes
(range, 78 to 161 min).
R esults
There was one death in the early post
operative period, unrelated to infection.
Among the 11 survivors there was no evid
ence of infective endocarditis at 3-month
postoperative follow-up.
The MIC and MBC were determined to
a maximum of 1:32. Eight of 10 patients
on ampicillin-cloxacillin prophylaxis had
adequate concentrations throughout. The
remaining two, with lower concentrations,
had received their last preoperative dose of
antibiotics 9 hours before cardiac bypass.
Similarly, low concentrations were achieved
in the two patients with lincomycin prophy
laxis although one of these had received ad
ditional drug intraoperatively.
Thus patients who received ampicillincloxacillin prophylaxis within 4 hours of
operation had adequate antistaphylococcal
activity in their serum throughout cardiac
bypass. Lincomycin prophylaxis gave less
satisfactory levels; however, the sample num
ber was small.
The cloxacillin values were more than
adequate to inhibit the growth of S. aureus,
cloxacillin-sensitive Staphylococcus alb us,
Streptococcus pyogenes and Diplococcus
pneumonia“• 6 throughout the period of
cardiac bypass provided the initial value was
within the therapeutic range. If serum cloxa
cillin concentrations were satisfactory at the
outset of cardiac bypass they remained so
throughout the period of the bypass. Blood
values are directly related to the time in
terval after the administration of the last
dose of antibiotic. These data are presented
in Fig. 1.
D iscussion
The value of prophylactic antibiotics in
surgery is in dispute. Some people believe
that antibiotics, used in this way, expose
the patient to the toxic and allergic risks
inherent in the administration of all anti
microbials, that they do not lower the rate
of infection, that the normal flora is eradi
cated, resistant bacteria proliferate and that
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these new opportunistic pathogens them
selves cause infection that is even more dif
ficult to treat. None the less in surgical
procedures associated with a high rate of
postoperative infection, the administration
of an antibiotic chosen for its effectiveness
against pathogens of importance in that par
ticular procedure has been associated with
a substantial reduction in the rate of in
fection.6-7
For procedures associated with a low in
fection rate similar information is lacking.
Goodman and coworkers8 attempted to do
a prospective study on the protective role
of antibiotics in cardiac surgery. Two cases
of potentially preventable D. pneumoniae
endocarditis occurred in a placebo group
and resulted in termination of the study
before any statistically valid conclusion
could be reached. Nevertheless this study
makes it difficult to justify a further similar
examination of this question in patients cur
rently undergoing heart valve replacement.
Current concern should be to define the
most appropriate drug, the ideal dosage,
and the best timing and duration of therapy.
The choice of ampicillin and cloxacillin at

0

2

4

our centre reflects the importance of gram
positive cocci, particularly S. aureus, S. epidermidis and streptococci in causing pros
thetic valvulitis.1' Lincomycin has a spec
trum of activity similar to that of cloxacillin
and is used in patients with a history of
penicillin allergy.
Our results indicate that the combination
of ampicillin and cloxacillin achieves satis
factory concentrations of activity against
penicillin-sensitive staphylococci even when
the last dose of drug is given some hours
before operation. However, in view of the
prevalence of penicillinase-resistant S. au
reus in hospitalized patients, blood con
centrations of cloxacillin alone are of ob
vious importance. It is apparent that to
achieve maximal blood concentrations of an
antibiotic it should be administered as close
to the time of operation as possible. Indeed
the two patients with no detectable cloxa
cillin in their blood stream had received
no antibiotic for 9 hours before operation.
These results are in keeping with a recent
study by Kluge and coworkers4 but differ
from an earlier study by Benner.3 Benner
found that, irrespective of prepump anti-

6

8

10

12

TIME IN HOURS
Fig. 1.—Serum cloxacillin concentrations are plotted for each patient at three time periods. “0”
represents time at which patient received last dose o f drug (0.5 g) before operation. Patients with
highest concentrations received drug shortly before operation. * = sample taken in recovery room.
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biotic blood concentrations, a precipitous
decline occurred with the initiation of car
diac bypass so that concentrations quickly
became inadequate. Benner did not inves
tigate the cause of the phenomenon; how
ever, refinements in cardiac bypass tech
nique as well as marked reduction in the
amount of blood used during operation may
explain this difference.
It is apparent that larger doses of cloxacillin could safely be used in this group of
patients. However, it is not clear that this
would offer any significant advantage. A
larger dose of ampicillin might extend its
spectrum of activity to sensitive Escherichia
coli, and nonpenicillinase-producing Proteus
spp. Although they are frequent colonizers
and cause urinary and respiratory tract in
fections among patients postoperatively,
these organisms are less important in the
etiology of valvulitis.1 Lincomycin, although
based on a small patient sample, does not
appear to provide adequate blood concentra
tions in the dosage used.
Most prophylactic regimens for openheart surgery are initiated in the 24 hours
before operation and continued for a vari
able length of time postoperatively. Re
stricting prophylaxis to the immediate pre
operative period attempts to avoid the
rapid change in endogenous microflora that
such therapy causes. This period might be
shortened further because the penicillins are
rapidly cleared from the blood stream and
interstitial concentrations lag behind those
of the serum by 1 to 2 hours.10
Experimental data from Burke’s study11
indicate that prophylaxis is most effective
around the time of contamination. If the
operative period is when major contamina
tion occurs, as Kluge and colleagues12 sug
gest, then this is a crucial time for intensive
prophylaxis. We therefore believe that the
addition of antibiotics intraoperatively is a
useful adjunct to heart valve replacement
surgery. How long such prophylaxis should
continue after operation in unclear. Pro
longed antimicrobial therapy is associated
with side effects including overgrowth by
resistant microorganisms, diarrhea, drug
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rashes, drug fever and superinfection. We
therefore discontinue such treatment once
the patient’s chest tubes and indwelling
catheters are removed, usually about the 4th
postoperative day. With this approach our
incidence of postoperative valvulitis over the
past year has been less than 1 %.
Our data indicate that, with current tech
niques, provided cloxacillin blood concen
trations are adequate at the onset of cardiac
bypass, they remain so throughout the opera
tive period. There appear to be no major
advantages to increasing the dose of cloxa
cillin above 0.5 g although this could safe
ly be done. Based on the findings in a
small number of patients, a 0.5-g dose
of lincomycin provides suboptimal therapy
for the eradication of S. aureus.
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DIFFUSE CAVERNOUS HEMANGIOMA OF THE SPLEEN
G. C. EJECKAM, MB, BS*
Diffuse hemangioma of the spleen occurred in
a 59-year-old man. The presenting features were
a dull ache and heaviness in the left upper
quadrant for 3 weeks, severe left-sided pain
and fever immediately before hospitalization, and
a tender mass in the left upper quadrant. The
condition was diagnosed at laparotomy; splenec
tomy was performed. In this case intrahemangiomatous hemorrhage had occurred, but not rup
ture of the spleen, which is a potentially lethal
complication. Other complications of diffuse
splenic hemangioma are thrombosis, infarction,
infection with abscess formation, and partial cal
cification of the vascular spaces. The condition
is rare; only 56 cases have been reported.
Un hemangiome diffus de la rate est apparu
chez un homme de 59 ans. Les symptomes comprenaient une douleur diffuse et une lourdeur
presentes depuis 3 semaines dans le quadrant
superieur gauche, une douleur severe du cote
gauche et de la fievre juste avant I'hospitalisation, et une masse sensible dans le quadrant
superieur gauche. Le diagnostic a ete pose a la
laparotomie: une splenectomie a ete effectuee.
Dans le present cas, une hemorragie hemangiomateuse est survenue sans qu'il y ait toutefois
rupture de la rate, cette complication pouvant
etre mortelle. Les autres complications de I'hemangiome diffus de la rate sont la thrombose,
I'infarctus, I'infection avec formation d’abces, et
une calcification partielle des espaces vasculaires. Cette affection est rare: seulement 56 cas
ont ete signales jusqu'a maintenant.

D if f u s e hemangioma of spleen is a rare
condition; by 1961 only 56 cases had
been reported in the world literature.1 Diag
nosis remains a problem and occasionally
exploratory laporotomy is required. This
case report illustrates some of the features
of the condition.

fore admission he experienced a sharp severe
pain on the same side and became febrile.
There were no urinary symptoms or change of
bowel habit and his appetite remained un
changed. Physical examination revealed a ten
der mass in the left upper quadrant; neither
jaundice nor generalized lymphadenopathy
were noted. The provisional diagnosis was
between malignant lymphoma and carcinoma
of colon. Results of barium enema examina
tion were normal. Exploratory laparotomy was
performed.
The spleen was found to be enlarged and
was removed. It weighed 530 g and measured
15 x 9 x 5 cm. The capsule showed patchy
fibrous thickening. Splenic tissue had been al
most completely replaced by multiloculated
hemorrhagic cysts (Fig. 1).
Microscopy revealed the features of diffuse
cavernous hemangioma (Fig. 2 ). The vascular
channels were lined by swollen or flat endo
thelial cells, and the parenchyma manifested
hemorrhage, with organization, and calcium de
position with giant-cell reaction (Fig. 3). Iron
and calcium stains were strongly positive.
D iscussion

Virchow2 recognized four types of splenic
hemangiomas: hemangioma simplex, caver
nous hemangioma, hemangioma telangiectoides and angioblastoma. The hemangioma
in the present case had elements of heman
gioma simplex and cavernous hemangioma.
Cavernous hemangiomas are uncommon in

C ase R e p o r t
A 59-year-old man was admitted to hospital
with a 3-week history of dull ache and heavi
ness in the left upper quadrant. Two days be*Resident, department of pathology, faculty of
medicine, University of Ottawa, and department
of laboratory medicine, Ottawa General Hospital,
Ottawa, ON.
Reprint requests to: Dr. G. C. Ejeckam, Depart
ment of pathology, Ottawa General Hospital, 43
Bruyere St., Ottawa, ON KIN 5C8.

Fig. 1.—Section through spleen showing multi
loculated hemorrhagic cystic spaces, with blood
clots within spaces. Note area of intact splenic
parenchyma on left.
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Fig. 2.—Features of cavernous hemangioma, with some capillary vascular formation. Fibrous
elements are increased in intervascular areas (hematoxylin and eosin, reduced by 15% from x 150).

Fig. 3.—Diffuse hemorrhage and organization. Note Gandy-Gamna bodies in parenchyma (hema
toxylin and eosin, reduced by 15% from x 60).
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the spleen: they may be asymptomatic
throughout life and only incidentally dis
covered at autopsy . 3 5 Occasionally splenic
enlargement is found during routine phys
ical examination or symptoms related to
splenomegaly are noted.6' 7 An enlarging
left upper abdominal mass, persistent or in
termittent pain, vomiting, dyspnea and pal
pitations, all, either individually or in com
bination, may indicate a splenic heman
gioma. In the patient whose case is re
ported herein, the sharp pain was probably
caused by hemorrhage into the angiomatous
spaces with sudden tension of the splenic
capsule.
Rupture of the spleen is a complication
of intrahemangiomatous hemorrhage. This
is fatal if unrecognized. The other chief
complications are thrombus formation, in
farction, infection with abscess formation
and partial calcification of vascular spaces.
The combination of focal fibrous scars con
taining deposits of hemosiderin and calcium
— Gandy-Gamna bodies — are indicative
of recurrent hemorrhages, organization of
blood in some of the hemangiomatous
spaces.
In the present case there was evidence of
a mild normocytic, normochromic anemia
but there were no target cells, schistocytes,
neutrophilia or thrombocytosis, indicating
autosplenectomy. Also absent were severe
anemia and consumption coagulopathy,
which have been described as presenting
clinical features . 8' 10
Splenic hemangiomas are benign tumours.
Reports of malignant transformation of
splenic hemangiomas11 14 must be as
sessed critically, as adequate documentation
is still lacking.
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I thank Dr. E. Liepa, department of pathology,
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sion to study the case files; Dr. G. Tolnai, de
partment of pathology, Ottawa General Hospital,
for his help and encouragement; Dr. D. Hill,
director of laboratory medicine, Ottawa General
Hospital, for his critical review; and the librarian
and secretaries, department of pathology, Ottawa
General Hospital, for their help in preparing this
manuscript.
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CONSERVATIVE MANAGEMENT OF EXTRAUTERINE PREGNANCY*
MICHAEL B. QUANE, MAO, FRCOG
A
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An abdominal pregnancy in a 28-year-old nulliparous woman with a fertility problem was
treated conservatively. The clinical antenatal
course was unremarkable. A healthy 2000-g in
fant was delivered at term by laparotomy. The
placenta was removed at the same time. Three
years later the patient had a ruptured tubal preg
nancy which was treated by salpingectomy. The
literature on extrauterine pregnancy is reviewed
briefly.
Line grossesse abdominale survenant chez une
nullipare de 28 ans qui presentait un probleme
de fertilite, a re?u un traitement conservateur.
L'evolution clinique prenatale a ete sans histoire. Un enfant de 2000 g en bonne sante a
ete accouche par laparotomie. Le placenta
a egalement ete retire. Trois annees plus tard,
la patiente a presente une grossesse tubaire
avec rupture qui a ete traitee par salpingectomie. La litterature sur la grossesse extra
uterine est revue brievement.

/
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T h e literature on the subject of extrauterine
pregnancy is pessimistic; maternal morbidity
is significant and fetal death rate is high.
Bright and Maser1 could find only 12 au
thentic case reports of abdominal pregnancy
with maternal and infant survival to 1961.
It is therefore understandable that few at
tempts have been made to treat cases diag
nosed in the first trimester conservatively.
Is conservative management of such cases
ever justifiable?

>
C ase R eport

The Clinical Course

J

4
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A 28-year-old nulliparous woman, with an
unremarkable past history, presented with a
fertility problem; she had been trying to be
come pregnant for 2 years, without success.
The physical findings, including a pelvic ex
amination under anesthesia, were unremark
able.
Carbon dioxide insufflation was carried out;
the gas passed with no demonstrable peris
talsis. An endometrical biopsy was done; the
curettings showed features consistent with

tubercular endometritis, but tubercle bacilli
were not identified. The patient was treated
with antituberculous drugs for 14 months,
after which endometrial biopsy and culture
were repeated and reported as normal.
The patient presented 5 months later with a
history of secondary amenorrhea for 6 Vi
weeks, intermittent nausea, slight urinary fre
quency and breast tenderness; she suspected
she was pregnant. Results of a complete gen
eral examination were normal.
The patient returned for follow-up 1 month
later with a 10-week history of amenorrhea,
slight backache, left lower quadrant discom
fort and slight bleeding for 12 hours.
Pelvic examination under anesthesia re
vealed a soft and slightly enlarged uterus and
a tangerine-sized solid mass of limited
mobility in the region of the left appendage.
The result of the urine pregnancy test was
positive and extrauterine pregnancy was sus
pected.
The patient and her husband wished the
pregnancy to continue despite the risks,
which were fully explained to them.
Probable genital tract turberculosis and a 4year history of infertility encouraged me to
agree with this decision; the chance for a
normal pregnancy was considered remote.
The patient remained in hospital for 9
weeks. In that time she remained well except
for a 2-week period of intermittent abdominal
discomfort associated with swelling of the
pregnancy mass to twice its usual size. The
swelling was resonant and soft; it subsided
following the passage of flatus and there was
no associated constipation, vomiting or pain.
At 19 weeks the patient was discharged
and followed on a weekly basis. The mass
continued to grow, but the patient complained
only of occasional abdominal discomfort. The
margins of the mass seemed to be irregular.
Initially it filled the left lower quad
rant; subsequently it crossed the midline at
the umbilicus, and became more symmetrical.
Fetal movements were first felt by the pa
tient at 14 weeks, and the fetal heart was
first heard at 29 weeks. The head engaged in
the pelvic brim at 34 weeks.

The Delivery
r
i

The patient was admitted to hospital for
elective laparotomy at term. Immediately be
Reprint requests to: Dr. M. B. Quane, 204 — fore laparotomy a blood transfusion was be
gun and the patient was examined vaginally.
1288 Summit Ave., Prince Rupert, BC V8I 2A5.

*From the department of obstetrics, Prince Rupert
Regional Hospital, Prince Rupert, BC.
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The uterus could not be outlined; the cervix
was not dilated and the fetal head, which was
in the pelvic cavity, had no direct relation to
the cervix, which lay to the front and slightly
to the left of the head.
The abdomen was opened through a ver
tical, subumbilical, midline incision. The fetus
lay longitudinally in the peritoneal cavity; an
incomplete sac had formed around it; the
pouch of Douglas was inferior; the posterior
leaf of the left broad ligament and the placenta
were anterior. The placenta had developed
normally on the posterior leaf of the left
broad ligament. The broad ligament itself had
been drawn high up into the peritoneal cavity,
and in this way formed much of the anterior
and left anterolateral wall of the sac. Su
periorly, the wall of the sac was formed by
the transverse colon and mesentery. The pos
terior parietal peritoneum formed the posterior
wall of the sac. The sac was formed on the
right side anterolaterally in part by adhesions
between the omentum and the small intestine.
The uterus lay above and slightly to the left
of the symphysis pubis. The right appendage
was free; the left appendage formed a part of
the mass including the broad ligament and
placenta.
The Baby
The infant was removed with ease by
dividing the loose adhesions between the small
intestine and the omentum on the right side.
The baby (a normally developed 2000-g fe
male) breathed spontaneously and remained
well.
The Placenta
A decision was made to remove the pla
centa. This was done by approaching it from
the attachment between the transverse colon
and its mesentery, and the amniotic mem
branes. The membranes were peeled off easily
with care taken to avoid damage to the mid
dle colic artery. Brisk bleeding was encountered
in separating the placenta from its main ma
ternal blood supply in the left broad ligament.
At this stage, the rate of blood transfusion
was increased by the application of positive
pressure. Hemostasis was secured by removing
the posterior portion of the left broad liga
ment and the left fallopian tube and ovary.
The abdomen was closed without drainage.
The patient’s general condition remained good
throughout. The estimated blood loss was 21;
5 units of blood had been transfused. The
mother’s convalescence was uneventful; the
mother and baby were discharged on the
18th day.
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Subsequent Course
Three years later, while on vacation, the
patient complained of vomiting, intermittent
abdominal pain relieved by frequent bowel
action, breast tenderness and amenorrhea for
5 weeks following a regular 26-day cycle. Non
specific gastrointestinal upset was diagnosed
and the patient was treated conservatively.
Her symptoms did not subside completely and
continued for 8 days, but she was well enough
to continue her vacation.
The abdominal pain recurred 4 days later
and was associated with slight vaginal bleed
ing and a recurring feeling of faintness. On
admission to hospital, a pelvic examination
was done and a right-sided appendage mass,
about the size of a hen’s egg, was palpated.
A blood transfusion was started and the ab
domen was opened; approximately 1.5 l
of free blood was found in the peritoneal
cavity. A rupturing pregnancy was noted at
the fimbriated end of the right tube; a right
salpingectomy was performed. At the time
of surgery, the previous operation site was
inspected and found to be healthy and clear
of adhesions. The convalescence was unevent
ful, and the patient was discharged from hos
pital 10 days later in good health.
Postscript
In the 7 years that have elapsed since the
birth of this baby, the child has remained
perfectly well. At the time of writing, the
child was considered to be physically normal
and of above-average intelligence. The pelvic
findings in the mother reverted to normal.
The endometrium has been biopsied and cul
tured twice in this time with negative re
sults. The mother’s general health has re
mained excellent.
D iscussion
Frequency of Extrauterine Pregnancy
It is difficult to obtain meaningful com
parative data on the frequency of abdominal
pregnancy because the statistics are reported
by a variety of authors in different ways.
Beecham and Beecham2 reported the fre
quency of abdominal pregnancy as 1 in
2081 births, while Eastman and Heilm an3
reported 1 in 15 000 deliveries and G rech4
recorded a hospital rate of 1 in 1814 ad
missions.
Discrepancies occur for three reasons.
First, abdominal pregnancy seems to be most
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often recorded in countries where medical
services are underdeveloped and where
records are sometimes inadequate. Second,
in relation to advanced abdominal preg
nancy, cases are recorded under two head
ings: abdominal pregnancy and extrauterine
gestation. These terms have been applied
loosely; for example, Naidu and Reddy0
recorded eight cases of advanced extraute
rine gestation, in which two of the preg
nancies had remained confined to one horn
of a bicornual uterus. Third, the term “ad
vanced” has been used by authors in dif
ferent ways: Clark and Bourke6 took it to
mean that the gestation period was over 12
weeks; M itra,7 over 51/2 months; and King*
used the term for gestations longer than 28
weeks.

Terminating Pregnancy
Current thinking tells us that the intra
abdominal pregnancy should be terminated
as soon as it is diagnosed, because of the
low fetal salvage rate and the high maternal
mortality and morbidity in late pregnancy.
Ziel9 reported a maternal mortality rate of
from 14 to 32% and a fetal mortality ap
proaching 100%. The chance of a baby
developing normally appeared to be about

10%.

►

►

y

Removal of the Placenta
It is widely believed that total removal
of the placenta lessens morbidity, even
though there is an associated high rate
of maternal mortality, secondary to hemor
rhage.
Most surgeons believe that all loose mem
branes of the sac should be removed, and
the cord, if left in situ, not ligated, because
of the possible subsequent development of
chorioamniotic cysts. If the placenta is
left in situ, absorption may occur as early
as 4 months and as late as 6 years after
delivery.
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Primary Peritoneal Implantation
Most cases of abdominal pregnancy are
secondary to peritoneal implantation of the
ovum. Though it is extremely doubtful if
primary peritoneal implantation ever occurs,
Miller10 recorded a 23-day pregnancy im
planted in the peritoneum below the right
uterosacral ligament; he was convinced that
this was a case of primary implantation.
Extra- and Intrauterine Pregnancy
Combined abdominal and intrauterine
pregnancy has been documented by Sehdev
and Sehdev;11 a liveborn male infant (weight,
1456 g) with no apparent congenital abnor
malities was delivered by cesarian section
and at the same time an 896-g male still
born with undescended testicles and a right
club foot was removed surgically from the
abdomen.
■»
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REVIEWS

D’ABREAU’S PRACTICE OF CARDIOTHORACIC SURGERY. 4th ed. J. Leigh Collis,
D. B. Clarke and R. Abbey Smith. 710 pp.
IIIlist. Edward Arnold (Publishers) Ltd.,
London; The Macmillan Company of Can
ada Limited, Toronto, 1976. $93.00.

This edition of professor d’Abreau’s text
book is again a useful description based on
experience in a single practice.
The section on pulmonary surgery is ex
cellent; the descriptions are practical and
oriented to patient management. The section
on valvular procedures, based on the author’s
experience, is informative and practical; on
the other hand, the chapters on congenital
heart disease, coronary artery disease and pace
makers, which reflect an admitted limited ex
perience, are inadequate. The book ends with
good sections on thoracic injuries, the eso
phagus and the diaphragm.
Although the sections on cardiac surgery
have limitations, those on thoracic surgery
are welcome. The single-author approach
avoids some of the errors, contradictions,
omissions or duplications of multiauthor text
books.
M. Brais

Department of cardiovascular and thoracic surgery,
Ottawa Civic Hospital,
Ottawa, ON.
ADVANCES IN CANCER SURGERY.
Edited by John S. Najarian and John P.
Delaney. 608 pp. lllust. Stratton Intercon
tinental Medical Book Corporation, New
York; Longman Canada Limited, Toronto,
1976. $28.50.

This volume was developed from a continuing
education course sponsored by the department
of surgery, University of Minnesota. It con
tains several groups of papers of varying qual
ity. The first group deals with principles of
cancer therapy including environmental car
cinogens, virology, cancer chemotherapy and
immunotherapy, radiotherapy and factors in
fluencing metastases. Subsequent sections are
organized on a systemic or regional basis.
These include discussions on various aspects
of the lymphomas, head and neck tumours,
cutaneous malignancies, intrathoracic tumours,
sarcomas and breast cancer. The final section
covers a variety of topics including groin and
axillary dissection, pediatric malignancies, intrascapulothoracic and hemipelvectomy ampu
tations, testicular and ovarian masses. Most
sections also contain a panel discussion, though

on three occasions the discussion concerns pa
pers that are located in later sections of the
book. Gastrointestinal, biliary, pancreatic and
hepatic malignancies are not discussed because
they were considered at an earlier course; sur
gical technique is not emphasized, though some
authors provide a few personal tips.
The book will not be attractive to the per
sonal libraries of most Canadian surgeons, as
most of the subjects are more throroughly
covered in standard texts and, of course, ab
dominal malignancies are omitted entirely.
Moreover, the publication of oral presenta
tions requires rigorous editing to achieve the
desirable degree of brevity.
J. E. D evitt
Director, Continuing medical education,
University of Ottawa,
Ottawa, ON.
ADVANCES IN NEPHROLOGY. Volume
5. From the Necker Hospital. Edited by
Jean Hamburger, Jean Crosnier and Morton
H. Maxwell. 364 pp. lllust. Year Book
Medical Publishers, Inc., Chicago, 1975.
$29.50.

This excellent review of advances in nephrology
is published annually from the Necker Hos
pital in Paris, France, under the auspices of
professor Hamburger. The nephrology group
of Necker Hospital has a wealth of both
clinical and laboratory experience in all areas
of nephrology; they are especially knowledgea
ble in the field of renal transplantation.
This year’s volume concentrates on glome
rular disease and renal transplantation. All of
the chapters are concisely and clearly written;
they will be easily understood by clinicians
working in these fields. The chapter on recent
advances in the understanding of rejection by
professor Hamburger is outstanding, and is
highly recommended to anyone seeking a cur
rent view of this phenomenon.
G eorge A. D e V eber

Toronto Western Hospital,
Toronto, ON.
CHEMOTHERAPY OF UROGENITAL TU 
MORS. Gerald P. Murphy and Arnold Mittelman. 268 pp. lllust. Charles C Thomas,
Publisher, Springfield, IL, 1975. $24.50.

This book is a monograph in the Bannerstone
division of American lectures in living
chemistry. This series was conceived to ad(Continued on page 366)
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vance the newer knowledge of chemical medi
cine in the cause of clinical practice, and this
book certainly fulfils that requirement. It joins
a rapidly growing number of books on cancer
chemotherapy and oncology, all of which
attempt to keep practising physicians upto-date in the rapidly changing field.
As noted in the foreword by Dr. Willet
Whitmore, “among the useful purposes served
by this volume are the collation and organiza
tion of the scattered and scant information
concerning the chemotherapy of urologic neo
plasms and the indication of the already im
plemented or proposed means of expanding
knowledge in this area”. The authors have en
listed the aid of Dr. Stephen Carter of the
National Cancer Institute, who has contributed
three chapters. Specific tumours covered in the
book include those of the kidney, prostate,
testicle and bladder, and squamous cell carci
noma, neuroblastoma, Wilms’ tumour and
adrenal tumours. There is also a chapter on
genitourinary sarcomas and other infrequent
neoplasms. The last chapter, on animal
models used for experimental chemotherapy of
genitourinary tract tumours, is a synopsis of
laboratory research being done in this area and
adds to the value of the presentation.
This small volume is clearly written, easy
to read and well illustrated. An excellent re
view of previous studies, it also fully docu
ments present efforts and makes recommenda
tions regarding future areas of research.
I strongly recommend this book to anyone
who is interested in the chemotherapy of these
tumours, particularly urologists, general sur
geons and medical oncologists.
D. J.

K

laassen

The Ontario Cancer Foundation,
Ottawa Clinic,
Ottawa, ON.
HAND SURGERY. 2nd ed. J. Edward Flynn.
712 pp. Hlust. The Williams & Wilkins
Company, Baltimore; Burns & MacEachern
Limited, Toronto, 1975. $53.50.
The first edition of Flynn’s textbook on hand
surgery received wide acceptance. W ith the
addition of 21 new contributors to the second
edition, the value of the textbook should be
enhanced. Each chapter is a well-written, selfcontained item by an authority on the subject.
For this reason it is not necessary to describe
highlights within the book. The format makes
for easy subject identification. To keep costs
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low, the print is small and the text is closely
packed, but once the reader becomes accus
tomed to this arrangement, it is quite ac
ceptable.
This book will be a welcome addition to
the library of the hand surgeon and should be
placed in all medical libraries as a valuable
reference source.
R. M. McF arlane
Department of surgery,
Victoria Hospital,
London, ON.
INSTRUCTIONAL COURSE LECTURES.
Volume XXIV, 1975. American Academy
of Orthopaedic Surgeons. 328 pp. Illust. The
C. V. Mosby Company, St. Louis, 1975.
$26.80.

The American Academy of Orthopaedic Sur
geons offers each year to the medical com
munity 120 instructional course lectures over
a 5-day period. A large number of formal
papers and audiovisual programs are included.
This text covers a few of the lectures. There
is no particular theme and the material is
selected at random. However, over the years
they have formed a collective review of cur
rent orthopedic topics. The material is of in
terest to all orthopedic surgeons but is aimed
primarily at residents and young orthopedists.
This year 30 acknowledged experts discussed
a wide range of topics; among these were
some of special interest such as biomaterials,
resistant congenital club foot, peripheral nerve
suture techniques, traumatic instability of the
wrist and surgical approaches to intrinsic
finger muscle dysfunction.
An annual series of lectures followed up by
a documentation of the better ones in this
way is a useful educational technique; other
specialties would do well to emulate this meth
od of postgraduate education.
L. H. Bartlett
Department of orthopedics,
Lions Gate Hospital,
North Vancouver, BC.
METHOD OF UROLOGY. Arthur W. Wyker,
Jr. and Jay Y. Gillenwater. 365 pp. Illust.
The Williams & Wilkins Company, Balti
more; Burns & MacEachern Limited,
Toronto, 1975. $17.60.

The authors have tried to provide a volume
that “fills the gap between the definitive refer
ence books and the simplified manuals”.
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“Method of Urology” is an outgrowth of the
teaching program at the University of Vir
ginia.
This book has many worthwhile features:
it supplies a useful review of recent urologic
thought, includes a concise, relevant and cur
rent bibliography at the end of each chapter
and is written clearly. However, it has some
drawbacks. First, unrelated topics, classifica
tions and points of interest are lumped together
into brief alternately numbered and lettered
paragraphs; this frequently confuses the is
sues involved. Second, the authors have tried
to include many points of view but have fre
quently failed to draw together and interpret
the data. Finally, too often the authors have
mixed anectodal information and scientific
fact.
Should further editions aim at correcting
some of the problems, the authors will have
made a significant contribution to the urologic
literature. In its present form the book is
useful; it does accomplish the authors’ stated
objectives.
B. M. M ount

Department of urology,
Royal Victoria Hospital,
Montreal, PQ.

POLYPOID LESIONS OF THE GASTROIN
TESTINAL TRACT. 2nd ed. Claude E.
Welch and Stephen E. Hedberg. Vol. II in
Major Problems in Clinical Surgery. 220 pp.
Illust. W. B. Saunders Company, Philadel
phia; W. B. Saunders Company Canada
Limited, Toronto, 1975. $13.90.

This small monograph is another definitive
work in the series entitled “Major Problems
in Clinical Surgery”, the second edition of
the Welch treatise of several years ago. A
major addition to the second volume of this
text results from the development of colono
scopy. Contained within this work is a de
scription of colonoscopy, detailed as though
the author were desirous of teaching everyone
this procedure. Its uses and its abuses are well
reviewed and the current state of the art is
well presented.
Definitions of the various types of polypoid
lesions, once again presented, still defy clarity
and precision, probably because the lesions
are not so distinct that they can be easily de
fined. Polypoid lesions are divided into adeno
matous, villoglandular, villous, polypoid and
malignant. An interlocking discussion shifts
back and forth between the various cate-
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gories, perhaps related to the changing criteria
of pathologists and uncertainties regarding the
malignant potential of the various pathologic
findings. There is a fairly long discourse on
the problems of cancer originating in polyps,
with a good discussion of the literature, and
a reasonably comprehensive statement of the
author’s own position on this complicated
topic.
The book departs from the issue of poly
poid lesions, per se, by providing recommenda
tions for the management of colonic polyps.
These are given by a thoughtful, careful ex
pert in the field, and are buttressed by an ex
tensive discussion of operative techniques;
once again this is probably too detailed for
those not conversant with the field, and in
sufficiently detailed for the expert surgeon.
The discussion concerning the remainder
of the gastrointestinal tract (esophagus through
small bowel) and the polypoid lesions occurring
within this segment of the intestinal tract is
less well done and less thorough than the
discourse on the colon.
The book contains a good bibliography and
is a handy reference work; probably it belongs
in the library of every surgeon who operates
on the colon.
C. B. M u e l l e r
Department of surgery,
McMaster University,
Hamilton, ON.
STRESS FRACTURES. Michael Devas. 240
pp. Illust. Churchill Livingstone, Edinburgh;
Longman Canada Limited, Toronto, 1975.
$54.00.

Stress fracture is too often not considered in
the differential diagnosis of diffuse aching
pain. Dr. Devas has in this short monograph
collected and categorized this type of injury
for us.
In the introduction the author describes the
pathogenesis of this type of injury so common
to the young and healthy. Signs and symptoms
are well described with adequate detail; the
value of these is reinforced by well-reproduced
radiographs. It is unfortunate that the excellent
figures are often widely separated from the
related text. There is at times a trend to re
dundancy because example cases are described
and the detail is repeated in the accompanying
radiograph. The author’s thoughts on cer
tain types of avascular necrosis being initiated
by compression-type stress fractures are inter
esting and worthy of further investigation.
This book brings to light, in a simple and
organized way, a collective reminder of a
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much forgotten injury. It serves to remind the
reader that the diagnosis of a stress fracture
must be suspected and made clinically.
M . A . R o sm a n

Division of orthopedic surgery,
Montreal Children’s Hospital,
Montreal, PQ.
SURGICAL DISORDERS OF THE PERI
PHERAL NERVES. 2nd ed. Sir Herbert
Seddon. 336 pp. Illust. Churchill Living
stone, Edinburgh; Longman Canada Lim
ited, Toronto, 1975. $43.25.

Except for a few changes, this second edition
of Seddon’s monograph appears to be identical
to the first. In some respects this lack of
change has led to omissions in the book’s con
tent. Thus, the recent advances in clinical
neurophysiology, microsurgical techniques and
perineural nerve repairs are alluded to in the
preface, but are not described in the text. Like
wise, "despite recent developments in the field,
the chapter on electrical phenomena is un
changed; intraoperative functional assessment
at the fascicular level is not referred to. The
work of Narakas on the surgical management
of brachial plexus injuries and of Millesi on
nerve grafts are detailed, but new microsuture
and microsurgical techniques for nerve repair
are barely mentioned; the section on operative
treatment is therefore somewhat out of date.
In spite of its limitations, this book is high
ly recommended to all concerned with the
repair of peripheral nerves; it is the most com
prehensive review on the subject of peripheral
nerve surgery to date and is an essential com
panion volume to Sunderland’s book “Nerves
and Nerve Injuries”.
J. K . T e r z is
Department of surgery,
Dalhousie University,
Halifax, NS.
TRANSPLANTATION TODAY. 3. Edited by
Michael Schlesinger, Rupert E. Billingham
and Felix T. Rapaport. 992 pp. Illust. Grune
& Stratton, Inc., New York; Longman Can
ada Limited, Toronto, 1975. $43.50.

There are few areas in medicine where the
applied science changes as rapidly as it does
in the field of transplantation. Several text
books have been written on transplantation by
physicians and surgeons over the last 10 years
and most of them now are of historical interest
only. It is of importance, therefore, that the
new information currently published in over
a dozen immunologic and clinical journals be
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brought together at regular intervals so that
physicians and medical scientists interested in
the applied aspects of transplantation can re
main abreast of the field.
The Transplantation Society (an interna
tional society embracing both basic scientists
and clinicians) meets every 2 years. Dr. Rapaport, who is editor of Transplantation Pro
ceedings, the official journal of the Transplanta
tion Society, has taken on the task of publish
ing the proceedings of the international meet
ing as an updated “textbook” of transplantation
in the year following the meeting of the so
ciety. This represents the third such issue.
Because the contents of this meeting contain
both invited papers and free communications,
the content is frequently highly technical and
of a basic science nature. Nevertheless, of the
992 pages in this volume, one-third of the
content is of direct interest to those doing
clinical transplantation.
The rapid changes occurring in the field of
histocompatibility make the introductory sym
posium on histocompatibility immunogenetics
and the section on the role of transplantation
antigens in human transplantation and sus
ceptibility to disease important for the reader
who wishes to update his knowledge in this
field.
A special section deals with tolerance or
enhancement as a solution to the clinical prob
lems of transplantation. We learn that the
in-vitro mechanisms elucidated from sophisti
cated studies may not be of great clinical
importance and that the real roles for the
delicate immunoregulatory mechanisms are
not yet understood.
The correlation of in-vitro immune responses
with clinical rejection is dealt with in detail.
It points up the weakness of looking at any
single part of a complex (immune) response,
in attempting to explain highly variable clin
ical courses. In spite of these negative find
ings, the reader is impressed with the abundant
scientific information and the potential of
applied assays in dissecting with greater ac
curacy the immune response in the transplant
recipient.
The section on clinical transplantation is a
follow-up report of 124 long-term transplants
of 8 to 12 years’ duration. Although gen
erally, patient survival was considerably less
in the period preceding 1966, the overall pa
tient survival was 56% in the related noniden
tical transplants and 41% in the cadaveric
transplants. The primary causes of death in
the long-term survivors were sepsis, late re
jection and liver failure. Interesting new areas
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of endeavour include the transplantation of
pancreatic islet cells with a resulting subse
quent correction of the renal lesion in diabetes.
The use of single allele shared skin allo
grafts for the treatment of burns is reported;
this is an area of great clinical promise. The
most significant advance at a clinically applied
level is in the field of bone-marrow transplan
tation. Several centres (primarily the Seattle
group) have demonstrated that bone-marrow
transplantation is the current treatment of
severe aplastic anemia.
It is essential, in my opinion, for any
clinical scientist interested in transplantation
to have available to him either in his own
library or through his local medical library
a copy of “Transplantation Today”, volume 3.
The information contained in this text is dated
but is still the most current available.
C. R. S t il l e r
Nephrology and transplai '.tion division,
University Hospital,
London, ON.
VASCULAR SURGERY. Edited by William
H. Edwards. 257 pp. lllust. University Park
Press, Baltimore, 1976. $24.50.

This book on vascular surgery covers a broad
range of topics. It is easy to read and provides
lessons from clinical experience by leading
vascular surgeons on techniques, diagnosis and
treatment.
The chapter on cerebrovascular insuffi
ciency is clear and concise; readers will find
it extremely helpful as a guide for the man
agement of these diseases.
The book contains illustrative case histories
of cerebrovascular occlusive disease; of special
interest are the case presentations of vertebro
basilar insufficiency and the subclavian steal
syndrome. Also useful are the many important
clinical points concerning aortoiliac and peri
pheral vascular diseases, the comprehensive
coverage of the management of renovascular
hypertension and the specific technical details
of surgery for resection o f common aneurysms.
The vascular injuries are well described;
this section includes both aortic and arterial
injuries and associated thromboembolism.
General surgeons who are practising vascular
surgery will find this book extremely helpful;
vascular surgeons will enjoy comparing their
own clinical experiences with those described
in this book.
M. A. N aqvi
336 Kings Road,
Sydney, NS.
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